WO2022051650A1 - Human monoclonal antibodies to sars-cov-2 and use thereof - Google Patents
Human monoclonal antibodies to sars-cov-2 and use thereof Download PDFInfo
- Publication number
- WO2022051650A1 WO2022051650A1 PCT/US2021/049112 US2021049112W WO2022051650A1 WO 2022051650 A1 WO2022051650 A1 WO 2022051650A1 US 2021049112 W US2021049112 W US 2021049112W WO 2022051650 A1 WO2022051650 A1 WO 2022051650A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- antigen
- cov
- antibody
- Prior art date
Links
- 230000027455 binding Effects 0.000 claims abstract description 295
- 239000000427 antigen Substances 0.000 claims abstract description 226
- 108091007433 antigens Proteins 0.000 claims abstract description 224
- 102000036639 antigens Human genes 0.000 claims abstract description 224
- 239000012634 fragment Substances 0.000 claims abstract description 224
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 174
- 238000011282 treatment Methods 0.000 claims abstract description 96
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 73
- 239000003814 drug Substances 0.000 claims abstract description 37
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 31
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 417
- 235000001014 amino acid Nutrition 0.000 claims description 166
- 238000000034 method Methods 0.000 claims description 139
- 150000001413 amino acids Chemical class 0.000 claims description 85
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 64
- -1 paraoxetine Chemical compound 0.000 claims description 62
- 208000015181 infectious disease Diseases 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 230000003612 virological effect Effects 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 26
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 229940096437 Protein S Drugs 0.000 claims description 22
- 101710198474 Spike protein Proteins 0.000 claims description 22
- 230000002685 pulmonary effect Effects 0.000 claims description 22
- 229920003169 water-soluble polymer Polymers 0.000 claims description 21
- 230000003247 decreasing effect Effects 0.000 claims description 18
- 230000001413 cellular effect Effects 0.000 claims description 17
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 16
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 238000001990 intravenous administration Methods 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 238000007918 intramuscular administration Methods 0.000 claims description 11
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000003001 serine protease inhibitor Substances 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 9
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 claims description 8
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 8
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 8
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 8
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 8
- 241000723346 Cinnamomum camphora Species 0.000 claims description 8
- 108010092160 Dactinomycin Proteins 0.000 claims description 8
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 claims description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 8
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 8
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 8
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 8
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 8
- 229960004150 aciclovir Drugs 0.000 claims description 8
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 8
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 8
- 229960003805 amantadine Drugs 0.000 claims description 8
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 8
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 8
- 229960004099 azithromycin Drugs 0.000 claims description 8
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 8
- 229940008411 baloxavir marboxil Drugs 0.000 claims description 8
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 229960000846 camphor Drugs 0.000 claims description 8
- 229930008380 camphor Natural products 0.000 claims description 8
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 8
- 229960004195 carvedilol Drugs 0.000 claims description 8
- 229960003677 chloroquine Drugs 0.000 claims description 8
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 8
- 229940087451 cytovene Drugs 0.000 claims description 8
- 229960000640 dactinomycin Drugs 0.000 claims description 8
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 8
- 229960001208 eplerenone Drugs 0.000 claims description 8
- 229950008454 favipiravir Drugs 0.000 claims description 8
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 8
- 229950002031 galidesivir Drugs 0.000 claims description 8
- 229960002963 ganciclovir Drugs 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 8
- 229940079322 interferon Drugs 0.000 claims description 8
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 8
- 229960002198 irbesartan Drugs 0.000 claims description 8
- 229950004244 laninamivir Drugs 0.000 claims description 8
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 8
- 229960003987 melatonin Drugs 0.000 claims description 8
- 229960000901 mepacrine Drugs 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- 229960001428 mercaptopurine Drugs 0.000 claims description 8
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004963 mesalazine Drugs 0.000 claims description 8
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 claims description 8
- 229950009865 nafamostat Drugs 0.000 claims description 8
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 8
- 229960003752 oseltamivir Drugs 0.000 claims description 8
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 claims description 8
- 229960001084 peramivir Drugs 0.000 claims description 8
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960000329 ribavirin Drugs 0.000 claims description 8
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 8
- 229960000888 rimantadine Drugs 0.000 claims description 8
- 229960000311 ritonavir Drugs 0.000 claims description 8
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 8
- 229960002930 sirolimus Drugs 0.000 claims description 8
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 8
- 229960005026 toremifene Drugs 0.000 claims description 8
- YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 claims description 8
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims description 8
- 229960004626 umifenovir Drugs 0.000 claims description 8
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 8
- 229960001028 zanamivir Drugs 0.000 claims description 8
- 229960002555 zidovudine Drugs 0.000 claims description 8
- 230000005847 immunogenicity Effects 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 230000001524 infective effect Effects 0.000 claims description 6
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 5
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000003018 immunoassay Methods 0.000 claims description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 230000002550 fecal effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims 7
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims 7
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims 7
- 229940122277 RNA polymerase inhibitor Drugs 0.000 claims 7
- 108091007520 SARS-CoV-2 RNA polymerases Proteins 0.000 claims 7
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 229940024606 amino acid Drugs 0.000 description 134
- 210000004027 cell Anatomy 0.000 description 92
- 210000004072 lung Anatomy 0.000 description 65
- 238000006467 substitution reaction Methods 0.000 description 62
- 241000700605 Viruses Species 0.000 description 48
- 229920001184 polypeptide Polymers 0.000 description 40
- 108090000765 processed proteins & peptides Proteins 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 241000699800 Cricetinae Species 0.000 description 39
- 230000000694 effects Effects 0.000 description 34
- 239000013598 vector Substances 0.000 description 31
- 238000003556 assay Methods 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 25
- 241000545067 Venus Species 0.000 description 25
- 230000035772 mutation Effects 0.000 description 25
- 210000001944 turbinate Anatomy 0.000 description 24
- 238000007912 intraperitoneal administration Methods 0.000 description 23
- 238000011068 loading method Methods 0.000 description 22
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 19
- 238000006386 neutralization reaction Methods 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 125000000539 amino acid group Chemical group 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 238000012423 maintenance Methods 0.000 description 17
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 16
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 16
- 102000048657 human ACE2 Human genes 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 238000011830 transgenic mouse model Methods 0.000 description 16
- 241000699660 Mus musculus Species 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 13
- 108010087819 Fc receptors Proteins 0.000 description 13
- 102000009109 Fc receptors Human genes 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 230000013595 glycosylation Effects 0.000 description 13
- 238000006206 glycosylation reaction Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- 241000494545 Cordyline virus 2 Species 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 12
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 241000711573 Coronaviridae Species 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 238000002203 pretreatment Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000000069 prophylactic effect Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 238000013507 mapping Methods 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 5
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 102220599656 Spindlin-1_E484K_mutation Human genes 0.000 description 5
- 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 102200128238 rs201124247 Human genes 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000008904 Betacoronavirus Species 0.000 description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102220480541 Endonuclease domain-containing 1 protein_G446V_mutation Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699673 Mesocricetus auratus Species 0.000 description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 102220562703 Protein Tob2_L234A_mutation Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000010530 Virus Neutralization Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 102200056390 rs12204826 Human genes 0.000 description 3
- 102220114694 rs763810935 Human genes 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 2
- 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 206010053172 Fatal outcomes Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102220599652 Spindlin-1_F490S_mutation Human genes 0.000 description 2
- 239000004138 Stearyl citrate Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012893 effector ligand Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000003771 laboratory diagnosis Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000008263 liquid aerosol Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102220277108 rs1553412687 Human genes 0.000 description 2
- 102200158818 rs35103459 Human genes 0.000 description 2
- 102200153441 rs768834663 Human genes 0.000 description 2
- 102220062574 rs770276731 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- AWAFMFHOLVZLFG-UHFFFAOYSA-N 1-iodoaziridine-2,3-dione Chemical group IN1C(=O)C1=O AWAFMFHOLVZLFG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102220579649 ATP-dependent RNA helicase A_K417N_mutation Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102400000347 Angiotensin 1-7 Human genes 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102220600740 Calmodulin-binding transcription activator 1_Q1E_mutation Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001461743 Deltacoronavirus Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000008920 Gammacoronavirus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000282317 Paguma larvata Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000006334 Phyllosma Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102220524643 Ribosomal protein S6 kinase beta-2_D31A_mutation Human genes 0.000 description 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
- 102220599627 Spindlin-1_D950N_mutation Human genes 0.000 description 1
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 1
- 102220590625 Spindlin-1_P26S_mutation Human genes 0.000 description 1
- 102220599609 Spindlin-1_P681R_mutation Human genes 0.000 description 1
- 102220590680 Spindlin-1_S13I_mutation Human genes 0.000 description 1
- 102220599630 Spindlin-1_T1027I_mutation Human genes 0.000 description 1
- 102220590621 Spindlin-1_T19R_mutation Human genes 0.000 description 1
- 102220590630 Spindlin-1_T20N_mutation Human genes 0.000 description 1
- 102220599418 Spindlin-1_V1176F_mutation Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102220635498 Vacuolar protein sorting-associated protein 33A_I34M_mutation Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940088990 ammonium stearate Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical compound [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 102220429344 c.456G>T Human genes 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical group O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical class [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- UGTYTOKVOXBJBZ-LINPMSLLSA-N peramivir hydrate Chemical compound O.O.O.O.CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N UGTYTOKVOXBJBZ-LINPMSLLSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108010017378 prolyl aminopeptidase Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102220053106 rs199537178 Human genes 0.000 description 1
- 102200000845 rs200678853 Human genes 0.000 description 1
- 102200144284 rs235768 Human genes 0.000 description 1
- 102220031793 rs431825282 Human genes 0.000 description 1
- 102220041275 rs587778692 Human genes 0.000 description 1
- 102220033185 rs62646881 Human genes 0.000 description 1
- 102220058675 rs786203529 Human genes 0.000 description 1
- 102220029076 rs78775072 Human genes 0.000 description 1
- 102200024304 rs886037751 Human genes 0.000 description 1
- 102220175504 rs886051197 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000001554 selenocysteine group Chemical group [H][Se]C([H])([H])C(N([H])[H])C(=O)O* 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- HFQQZARZPUDIFP-UHFFFAOYSA-M sodium;2-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O HFQQZARZPUDIFP-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940029614 triethanolamine stearate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- Coronaviruses are members of the family Coronaviridae.
- the Coronaviridae has 4 separate genera, the Alphacoronavirus, Betacoronavirus, Deltacoronavirus, and Gammacoronavirus with each genus having one or more subgenus.
- the Alphacoronaviruses and Betacoronaviruses mainly infect bats, but they also infect other species such as humans, camels, rabbits, dogs and masked palm civets.
- CoVs are enveloped viruses that possess extraordinarily large single-stranded RNA genomes ranging from 26 to 32 kilobases in length. CoVs were historically regarded as pathogens that only cause mild diseases. Currently, at least seven CoV species are known to cause diseases in humans.
- HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKUl generally cause only mild common cold symptoms. Severe illness can be caused by the remaining three viruses, each in the Betacoronavirus genus. SARS-CoV resulted in the outbreak of sever acute respiratory syndrome (SARS) in 2002 and 2003. MERS-CoV was responsible for Middle East respiratory syndrome (MERS), which emerged in 2012 and remains in circulation in camels. A small outbreak of MERS-CoV was reported on June 2, 2020 in Saudi Arabia (9 case reported with 5 deaths). Finally, SARS-CoV-2, which emerged in December 2019 in Wuhan province of China, and causes COVID-19. The COVID-19 pandemic is impacting virtually every country around the world, with no immediate prospects for easing. The US is currently topping the world in the number of infected people with more cases in sight.
- SARS-CoV-2 has a basic reproduction rate (Ro) of 3.3-5.5, which is higher than those of SARS-CoV and MERS-CoV (2.7-3.9), indicating a higher transmissibility of SARS-CoV-2 than other human coronaviruses.
- Ro basic reproduction rate
- COVID 19 has currently infected more than 16,000,000 individuals and has been responsible for over 650,000 deaths worldwide.
- FIG. 1 shows the ELISA binding profile of antibodies of the disclosure for binding to recombinant SARS-CoV-2 spike proteins.
- FIG. 2 shows binding of antibodies of the disclosure to SARS-CoV-2 infected cells.
- FIG. 3 depicts the high affinity of certain mAbs for SARS-CoV-2 Spike Receptor Binding Domain. Binding to SARS-CoV-2 RBD was determined by surface plasmon resonance (SPR).
- FIGS. 4A-4D depict rationally designed 1212C2 mAb variants with increased neutralization activity.
- Fig. 4A shows the sequences of 1212C2 mAb and variants thereof.
- Fig. 4B, 4C and 4D show viral neutralization by 1212C2, 1212C2-V1, and 1212C2-V2 mAbs, respectively.
- FIG. 5A-5D shows prophylactic and therapeutic activity of 1212C2 hmAb in SARS-CoV- 2-infected hamsters.
- Golden Syrian hamsters were (Fig. 5 A) prophylactically treated i.p. with 10 mg/kg indicated hmAb or PBS 6 h before intranasal (i.n.) challenge with 2 x 10 5 PFU SARS-CoV- 2 or (Fig. 5B) therapeutically treated by intraperitoneal (i.p.) injection with 25 mg/kg indicated hmAb or PBS 6 h following i.n. challenge with SARS-CoV-2. Virus present in nasal turbinates and lungs was determined by plaque assay. Dotted line indicates limit of detection.
- FIGS. 6A - 6C show therapeutic activity of inhaled 1212C2 hmAb in SARS-CoV-2- infected hamsters.
- Golden Syrian hamsters were infected i.n. with 2 x 105 PFU SARS-CoV-2 and 12 h later treated with indicated hmAb by i.p. or inhaled administration.
- Virus present in nasal turbinates and lungs was determined by plaque assay at 2 dpi (Fig. 6A) and 4 dpi (Fig. 6B). Dotted line indicates limit of detection.
- Fig. 6C Distribution of pathologic lesion were measured using ImageJ and represented as the percentage of the total lung surface area. *p ⁇ 0.0055 and **p ⁇ 0.00055 compared to PBS i.p. -treated group determined by 2-tailed t test.
- FIG. 7 shows the preservation of body weight with inhaled therapeutic treatment of SARS-
- FIGS. 8A-8H show prophylactic activity of 1212C2 in mice infected with SARS-CoV-2.
- Figs. 8 A and 8B five-week-old KI 8 hACE2 transgenic mice were injected with isotype IgG control or 1212C2 MAbs and 12 h after treatment, mice were infected (10 5 PFU/mouse) with recombiant SARS-CoV-2/Nluc-2A (Nluc-2A). Mock-treated and mock-infected mice were included as controls. Mice were anesthetized at 1, 2, 4 and 6 dpi and retro-orbitally injected with the Nluc substrate.
- Nluc expression was determined using an IVIS system (Fig. 8A) and quantitively analyzed by the Aura program (Fig. 8B). The lungs were excised and photographed at 1, 2, 4 and 6 dpi (Fig. 8C) and the gross lesions on the lung surfaces were quantitively analyzed by ImageJ (Fig. 8D). ns, not significant. Nluc activity in the nasal turbinate (left), lungs (middle) and brains (right) from infected mice were measured using a multi-plate reader (Fig. 8E). Viral titers in the nasal turbinate (left), lungs (middle) and brain (right) were determined by plaque assay (Fig. 8F).
- mice Five-week-old K18 hACE2 transgenic mice were injected with isotype IgG control or 1212C2 MAbs and 12 h after treatment, mice were infected (10s PFU/mouse) with rSARS-CoV-2/Nluc-2A (Nluc-2A). Mock-treated and mock-infected mice were included as controls. Mice were monitored for 12 days for changes in body weight 1 (Fig. 8G) and survival (Fig. 8H).
- FIGS. 9A and 9B show prophylactic activity of 1212C2 and 1213H7 against SARS-CoV- 2 WT and SARS-CoV-2 Beta (SA) in KI 8 hACE2 transgenic mice.
- FIGS. 10A and 10B show inhibition of SARS-CoV-2 lung viral burden in mice by 1212C2 and 1213H7.
- lungs were collected to determine Venus and mCherry fluorescence expression using an Ami HT imaging system (A).
- A Ami HT imaging system
- B Mean values were normalized to the autofluorescence in mock-infected mice at each time point and were used to calculate fold induction.
- Gross pathological scores in the lungs of mock-infected and rSARS-CoV- 2-infected KI 8 hACE2 transgenic mice were calculated based on the % area of the lungs affected by infection.
- FIGS. 11A-11D show viral titers in the lungs, nasal turbinate and brain of KI 8 hACE2 transgenic mice treated with 1212C2 or 1213H7 mAbs and infected with rSARS- CoV-2 WT and rSARS-CoV-2 Beta.
- Viral titers in the lungs (top), nasal turbinate (middle) and brain (bottom) at days 2 and 4 pi were determined by plaque assay in Vero E6 cells. Bars indicates the mean and SD of lung virus titers. Dotted lines indicate the limit of detection.
- Figure 11D shows quantification of rSARS-CoV-2 Venus (WT) and rSARS-CoV-2 mCherry SA (Beta) in the lungs (top), nasal turbinate (middle) and brain (bottom) from mice co-infected with both rSARS-CoV-2 Venus (WT) and rSARS-CoV-2 mCherry SA (Beta) at days 2 and 4 pi.
- FIG. 12 shows mAb binding to RBD variants.
- SARS-CoV-2 RBD variants 50nM were injected over mAbs captured on a biacore chip and their binding levels measured and normalized to the binding response to a reference (WT) Wuhan-1 RBD.
- WT reference
- Two WT RBD binding experiments were performed at the beginning and end of the experiment to validate the reproducibility of the assay.
- mAb binding is presented in the matrix as % of WT binding.
- FIGS. 13A-13D show mAb epitope mapping. Competition epitope mapping using SPR, combined with the previously described variant analysis were used to define the binding epitopes of the mAbs.
- FIGS. 13A-13C represent 3 distinct competition mapping experiments performed with hmAbs assigned to different epitope classes Cl, CID, C2, or C4.
- FIG. 13D shows structural models of the mAb/RBD complexes that explain the epitope mapping and variant binding data. Protein data bank (PDB) entries used to model the mAb/RBD complexes are underlined in the Figure.
- PDB Protein data bank
- FIG. 14 shows MARM analysis of SARS-CoV-2 mAbs.
- Vero E6 cells were infected with SARS-CoV-2 WA-1 and incubated with decreasing concentration of mAb.
- Virus that emerged resistant to the indicated mAb was tested for recognition by the mAb using immuno-fluorescence assay (top).
- the spike of the MARMs was sequenced and mutation noted. Mutations within the RBD are indicated in bold (bottom).
- FIG. 15 shows the results of study 2020-20, in particular differential biodistribution and titer of an IgG mAb in serum, bronchial tissue and lung at 0.5, 6, 12 and 24hrs post administration in mouse after administration by IV, IN and IH routes.
- FIGS. 16A-16G show representative wells and mAh dose plotted against percent viral infection pre- and post-treatment for a neutralizing antibody assay involving treatment with 1212C2 (A), 1213H7 (B), 1215D1 (C), 1212C2+1213H7 (D), 1213H7+1215D1 (E), 1212C2+1215D1 (F), and 1212C2+1213H7+1215D1 (G).
- the disclosure provides for broadly neutralizing anti-SARS-CoV-2 monoclonal antibodies and antigen-binding fragments thereof.
- the disclosure further provides for pharmaceutical compositions comprising an antibody of the disclosure and methods of using the antibodies of the disclosure.
- the antibodies of the disclosure are shown to be effective in preventing a SARS-CoV- 2 infection as well as in treating a SARS-CoV-2 infection.
- the antibodies of the disclosure bind epitopes within the spike protein of SARS-CoV-2.
- the antibodies of the disclosure bind an epitope within the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
- the antibodies of the disclosure bind an epitope within the receptor binding moiety (RBM) of the SARS-CoV-2 spike protein.
- the antibodies of the disclosure bind an epitope within the S 1 region of the SARS-CoV-2 spike protein. In certain embodiments, the antibodies of the disclosure bind an epitope within the S2 region of the SARS-CoV-2 spike protein.
- the antibodies of the disclosure reduce binding of SARS-CoV-2 to a target cell. In certain embodiments, the antibodies of the disclosure reduce cellular fusion between SARS-CoV-2 and a target cell. In certain embodiments, the antibodies of the disclosure reduce release of infective SARS-CoV-2 from an infected cell. In certain embodiments, the antibodies of the disclosure reduce infection of a target cell by SARS-CoV-2.
- the antibodies of the disclosure were isolated from a subject with a documented SARS-CoV-2 infection, wherein the subject subsequently recovered from the SARS-CoV-2 infection. As such, the subject mounted an effective immunological response to the SARS-CoV-2 infection. Using single-cell immunoglobulin cloning, neutralizing antibodies to SARS-CoV-2 were isolated from the subject.
- the term “about” refers to within 10%, preferably within 5%, and more preferably within 1% of a given value or range. Alternatively, the term “about” refers to within an acceptable standard error of the mean, when considered by one of ordinary skill in the art.
- affinity refers to the strength of the sum total of noncovalent interactions between a single binding site of an antibody or other molecule and its binding partner (such as, but not limited to, an antigen).
- binding affinity refers to intrinsic binding affinity which reflects a 1 : 1 interaction between an antibody and an antigen or between members of a binding pair. Affinity is generally be represented by the dissociation constant (KD).
- antibody includes whole antibodies and any antigen binding fragment thereof.
- examples of an antibody include, but are not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (for example, bispecific antibodies) formed from at least two antibodies or antigen binding fragments thereof, chimeric antibodies, anti -idiotypic (anti-Id) antibodies, intrabodies, and antigen binding fragments of any of the foregoing,
- Whole antibodies are glycoproteins comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
- Each heavy chain is comprised of a heavy chain variable (VH) region and a heavy chain constant (CH) region.
- the CH region is comprised of three to four domains, CHI, CH2, CH3, and CH4.
- Each light chain is comprised of a light chain variable (VL) region and a light chain constant region.
- the light chain constant region is comprised of one domain, CL.
- the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs).
- CDRs complementarity determining regions
- FRs framework regions
- Each VH and VL region is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
- the VH and VL regions form a binding domain that interacts with an antigen in an antigen-specific manner.
- the CH and CL regions mediate binding of the antibody to host tissues, cells or factors, including various cells of the immune system (e.g, effector cells) and the first component (Clq) of the classical complement system.
- Antibodies may be of any type, including IgG, IgE, IgM, IgD, IgA and IgY and of any class, including, class IgGl, IgG2, IgG3, IgG4, IgAl and IgA2 or subclass.
- the terms “antigen-binding fragment” or “antigen-binding portion” refer to one or more fragments derived from an antibody described herein (a parent antibody) that retain the ability to specifically bind to the same antigen as the parent antibody.
- binding fragments include, but are not limited to, a Fab fragment (a monovalent fragment consisting of the VL, VH, CL and CHI domains), a F(ab)2 fragment (a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region), a Fab' fragment (an Fab fragment comprising a portion of the hinge region), a F(ab’)2 fragment (a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region and containing a portion of the hinge region) a Fd fragment (a monovalent fragment consisting of the VH and CHI domains), a Fv fragment (a monovalent fragment consisting of the VL and VH domains of a single arm of an antibody
- the terms also include single chain Fv (scFv) which are created by recombinantly joining the VH and VL genes by a synthetic linker and expressed as a single polypeptide.
- scFv include, but are not limited to, scFv-FC, scFv- CH, scFab, and scFv-zipper.
- An antigen-binding fragment as described herein may be obtained using conventional methods known in the art and tested for binding as is done with conventional whole antibodies. Suitable antigen-binding fragments are described in Pluckthun (The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp.
- an antibody of the disclosure means an antibody disclosed herein, and includes pharmaceutically acceptable forms thereof, such as, but not limited to, pharmaceutically acceptable salts, hydrates and/or solvates.
- an antibody of the disclosure is an antigen-binding fragment.
- antibody variant refers to any modified form of an antibody described herein, such as, but not limited to, an antibody having one or more substitutions, deletions or insertions relative to a parental antibody and an antibody linked to a protein or nonprotein moiety.
- the terms “binds to an epitope” or “recognizes an epitope” with reference to an antibody refers to the epitope bound by the antibody. The term does not require the antibody to directly contact every amino acid within the epitope.
- the term “binds to the same epitope” with reference to two or more antibodies means that the antibodies bind to the same or overlapping amino acids, whether such amino acids are continuous or discontinuous segments. The term does not require the antibodies bind to or contact exactly the same amino acids. The precise amino acids which the antibodies contact can differ.
- a first antibody can bind to a group of amino acids that is completely encompassed by the group of amino acids bound by a second antibody.
- a first antibody can bind to a group of amino acids that overlap with a group of amino acids bound by a second antibody.
- chimeric antibody refers to an antibody in which at least a portion of the variable region sequences (including CDR and FR sequences or just CDR sequences) are derived from one species (for example, a rat) and the constant region sequences are derived from another species (for example, a human).
- the term also includes an antibody in which its variable region sequence or CDR(s) is derived from one source (e.g., an IgAl antibody) and the constant region sequence or Fc is derived from a different source (e.g., a different antibody, such as an IgG, IgA2, IgD, IgE or IgM antibody).
- Chimeric antibodies are described in U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81 :6851-6855 (1984)).
- the term “detectable label” refers to a molecule capable of being detected in a subject or an assay, including, but not limited to, radioactive isotopes, fluorescent compounds, chemiluminescent compounds, chromophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, chromophores, dyes, metal ions, metal sols, ligands, intercalating dyes and the like.
- epitope refers to an antigenic determinant that interacts with (is bound by) a specific antigen binding site in the variable region of an antibody molecule (the paratope).
- a single antigen such as, but not limited to, a polypeptide
- different antibodies may bind to different epitopes on an antigen and may have different biological effects depending on which epitope is bound.
- epitope also refers to a site on an antigen to which B and/or T cells respond. It also refers to a region of an antigen that is bound by an antibody.
- Epitopes may be defined as a structural epitope (the portion of the antigenic determinant that is contacted by the CDR loops of an antibody) or a functional epitope (a subset of a structural epitope comprising those energetic residues centrally located in the structural epitope and directly contribute to the affinity of the antibody-epitope interaction). Epitopes may become immunologically available after fragmentation or denaturation of an antigen (a cryptotope). Epitopes may be linear or conformational (composed of non-linear amino acids brought together in a folded three-dimensional structure).
- Epitopes may include residues that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and may have specific three-dimensional structural characteristics, and/or specific charge characteristics.
- An epitope typically includes at least 3 to 15 amino acids.
- epitope mapping refers to the process of identification of an epitope for antibody-antigen recognition.
- the term “functional equivalent” with reference to an antibody disclosed herein refers to an antibody variant of a parent antibody that retains one or more characteristics (such as, but not limited to, binding to the same epitope) of the parent antibody as disclosed herein.
- a functional equivalent may optionally differ in one or more characteristics of the parent antibody (such as, but not limited to, binding affinity, ADCC, and/or CDC).
- human antibody refers to antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. Human antibodies can include amino acid residues not encoded by human germline immunoglobulin sequences (such as mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). As used herein, the term human antibody is not intended to include antibodies in which CDR sequences are derived from the germline of another mammalian species, such as a mouse, that have been grafted onto human framework sequence and/or constant regions.
- human monoclonal antibody refers to a monoclonal antibody that is obtained from a human.
- the term “immune response” refers to a biological response within a vertebrate against a foreign agent, which response protects the vertebrate, at least partially, against the foreign agent and diseases caused by the foreign agent.
- An immune response is mediated by the action of a cell of the immune system (for example, a T lymphocyte, B lymphocyte, natural killer (NK) cell, macrophage, eosinophil, mast cell, dendritic cell or neutrophil) and soluble macromolecules produced by any of these cells or the liver (including antibodies, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and/or elimination from the vertebrate’s body of invading foreign agent, cells or tissues infected with the foreign agent.
- the term “immune response” does not include a response to a self-antigen.
- isolated antibody refers to an antibody that is substantially free of other antibodies having different antigenic specificities.
- An isolated antibody can optionally be substantially further free of other cellular material and/or reagents.
- isotype refers to the antibody class (IgG, including IgGl-IgG4, IgM, and IgA. Including IgAl and IgA2, IgD and IgE) that is encoded by the heavy chain constant region genes.
- K ass oc and “K a ” refer to the association rate of a particular antibody-antigen interaction.
- Kdis or “Kd” refer to the dissociation rate of a particular antibody-antigen interaction.
- KD refers to the dissociation constant, which is obtained from the ratio of Kd to K a and is expressed as a molar concentration (M).
- the term “monoclonal antibody” refers to antibody molecules of a single molecular composition such that each of the antibody molecules displays a single binding specificity and binding affinity for a given epitope.
- pharmaceutically acceptable refers to a compound that is compatible with an antibody of the disclosure or other ingredients of a composition and not deleterious to the subject receiving the antibody of the disclosure or composition.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- the term “pharmaceutically acceptable carrier or excipient” refers to a carrier medium or an excipient which does not interfere with the effectiveness of an antibody of the disclosure or other active ingredient of the composition and which is not toxic to the subject at the concentrations at which it is administered.
- the term includes, but is not limited to, a solvent, a stabilizer, a solubilizer, a tonicity enhancing agent, a structure-forming agent, a suspending agent, a dispersing agent, a chelating agent, an emulsifying agent, an anti-foaming agent, an ointment base, an emollient, a skin protecting agent, a gel-forming agent, a thickening agent, a pH adjusting agent, a preservative, a penetration enhancer, a complexing agent, a lubricant, a demulcent, a viscosity enhancer, a bio-adhesive polymer, or a combination thereof.
- a solvent e. W. Martin, 18 th Ed., 1990, Mack Publishing Co.: Easton, Pa.
- the term “pharmaceutically acceptable salt” refers to salts derived from inorganic or organic acids including, for example hydrochloric, hydrobromic, sulfuric, nitric, perchloric, phosphoric, formic, acetic, lactic, maleic, fumaric, succinic, tartaric, glycolic, salicylic, citric, methanesulfonic, benzenesulfonic, benzoic, malonic, trifluoroacetic, trichloroacetic, naphthalene-2 sulfonic and other acids.
- Pharmaceutically acceptable salt forms may also include forms wherein the ratio of molecules comprising the salt is not 1: 1.
- the salt may comprise more than one inorganic or organic acid molecule per molecule of antibody, such as two hydrochloric acid molecules per molecule of antibody.
- the salt may comprise less than one inorganic or organic acid molecule per molecule of antibody, such as two molecules of compound of antibody per molecule of tartaric acid. Salts may also exist as solvates or hydrates.
- a “pharmaceutical composition” refers to a mixture of one or more of the antibodies of the disclosure, with other components, such as, but not limited to, pharmaceutically acceptable carriers and/or excipients.
- the purpose of a pharmaceutical composition is to facilitate administration of a compound of disclosure.
- the term “recombinant antibody” includes all antibodies that are prepared, expressed, created or isolated by recombinant means, such as, but not limited to, antibodies isolated from an animal that is transgenic or transchromosomal or a hybridoma prepared therefrom, antibodies isolated from a host cell transformed to express the antibody (a transfectoma), antibodies isolated from a recombinant or combinatorial antibody library, and antibodies prepared or created by any means involving the splicing of immunoglobulin gene sequences to other DNA sequences.
- Such recombinant antibodies may be human recombinant antibodies.
- Such recombinant antibodies can be subjected to in vitro mutagenesis or in vivo somatic mutagenesis.
- the term “subject” refers to an animal.
- the animal is a mammal.
- a subject also refers to for example, primates (e.g, humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
- the subject is a human.
- the term “therapeutically effective amount” refers to an amount of an antibody of the disclosure that is sufficient to achieve a beneficial or desired result, including a clinical result.
- the “therapeutically effective amount” may be sufficient, for example, to reduce or ameliorate the severity and/or duration of a SARS-CoV-2 infection, or one or more symptoms thereof, prevent the recurrence, development, or onset of one or more symptoms associated with a SARS-CoV-2 infection, prevent or reduce the replication or multiplication of SARS-CoV, prevent or reduce the production and/or release of a SARS-CoV-2 particle, or enhance or otherwise improve the prophylactic or therapeutic effect(s) of another therapy used in treating a SARS-CoV-2 infection.
- a “therapeutically effective amount” is an amount of the antibody of the disclosure that avoids or substantially attenuates undesirable side effects.
- the “therapeutically effective amount” in the context of a SARS- CoV-2 infection is an amount sufficient to reduce one or more of the following steps of a the life cycle of SARS-CoV-2: the docking of the virus particle to a cell, the introduction of viral genetic information into a cell, the expression of viral proteins, the translation of viral RNA, the transcription of viral RNA, the replication of viral RNA, the synthesis of new viral RNA, the production of new virus particles and the release of virus particles from a cell.
- Such a reduction in any of the foregoing may be by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%.
- the “therapeutically effective amount” in the context of a SARS- CoV-2 infection reduces the replication, multiplication or spread of the virus by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%.
- the “therapeutically effective amount” in the context of a SARS-CoV-2 infection increases the survival rate of infected subjects by at least 5%, preferably at least 10%, at least 15%, atleast 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%.
- a reduction of increase when a reduction of increase is specified, such reduction of increase may be determined with respect to a subject that has not been treated with an antibody of the disclosure and that has a diagnosed SARS-CoV-2 infection.
- beneficial or desired clinical results in the context of a SARS-CoV-2 infection include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, a diminution of extent of disease, a stabilized (z.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state and remission (whether partial or total), whether detectable or undetectable.
- Treatment or “treating” can also mean prolonging survival as compared to expected survival if not receiving treatment.
- the disclosure provides the following neutralizing SARS-CoV-2 antibodies that specifically binds to the spike protein of SARS-CoV-2: 1212C2, 1212F5, 1213H7, 1212F2, 1206D1, 1212D5, 1207B4, 1213F2, 1212D4, 1206A5, 1212D6, 1206D12, 1207F10, 1206G12, 1212C8, 1212E9, 1214E9, and 1215D1.
- an antigen binding fragment of the antibodies 1212C2, 1212F5, 1213H7, 1212F2, 1206D1, 1212D5, 1207B4, 1213F2, 1212D4, 1206A5, 1212D6, 1206D12, 1207F10, 1206G12, 1212C8, 1212E9, 1214E9, and 1215D1 is provided.
- the antibodies are human monoclonal antibodies and/or the antigen binding fragments are derived from human monoclonal antibodies.
- Table 1 provides the SEQ ID NOS: for the nucleotide sequence (NT) of the heavy chain variable regions and light chain variable regions, the amino acid (AA) sequence of the heavy and light chain variable regions, the AA sequence of the heavy chain CDR1, CDR2, and CDR3, and the AA sequence of the light chain
- the neutralization titer 50 (NT50) of the antibodies of the disclosure ranges from less than 0.050 pg/ml to 1.61 gg/ml.
- the NT50 value if the antibodies of the disclosure is less than or equal to 10 pg/ml, less than or equal to 8 pg/ml, less than or equal to 6 pg/ml, less than or equal to 4 pg/ml, less than or equal to 3 pg/ml, less than or equal to 2 gg/ml, or less than or equal to 1 gg/ml.
- the NT50 value if the antibodies of the disclosure is less than or equal to 0.5 pg/ml, less than or equal to 0.25 pg/ml, less than or equal to 0.1 pg/ml, less than or equal to 0.075 pg/ml, less than or equal to 0.05 pg/ml, less than or equal to 0.025 pg/ml, or less than or equal to 0.01 pg/ml.
- NT50 values are determined as described in Example 4 of the disclosure.
- the disclosure provides an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, the isolated antibody, or the antigen-binding fragment thereof, comprising: 1. (i) a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 38-40, respectively, and (ii) a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 42-44, respectively (1212C2);
- a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 46-48, respectively, and
- a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 50-52, respectively (1215F5);
- a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 126-128, respectively, and
- a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 130-132, respectively (1206D12);
- a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 142-144, respectively
- a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 146-148, respectively (1206G12), or a pharmaceutically acceptable form of any of the foregoing, such as, but not limited to a pharmaceutically acceptable salt, solvate and/or hydrate.
- the disclosure provides an isolated antibody, or an antigenbinding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, the isolated antibody, or the antigen-binding fragment thereof, comprising: 1. (i) a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 37, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 41, or an amino acid sequence at least 80% homologous thereto (1212C2);
- a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 93, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 97, or an amino acid sequence at least 80% homologous thereto (1213F2); (i) a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 101, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 105, or an amino acid sequence at least 80% homologous thereto (1212D4); (i) a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 109, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 113, or an amino acid sequence at least 80% homologous thereto (1206
- a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 155, or an amino acid sequence at least 80% homologous thereto
- a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 156 (1212C8), or an amino acid sequence at least 80% homologous thereto, or a pharmaceutically acceptable form of any of the foregoing, such as, but not limited to a pharmaceutically acceptable salt, solvate and/or hydrate.
- the disclosure provides an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, the isolated antibody, or the antigen-binding fragment thereof, comprising:
- a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 158, 39 and 159, respectively
- a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 42, 43, and 161, respectively (1212 variant), or a pharmaceutically acceptable form of any of the foregoing, such as, but not limited to a pharmaceutically acceptable salt, solvate and/or hydrate.
- the amino acid at position 3 of SEQ ID NO: 158 is Thr (T) or He (I)
- the amino acid at position 1 of SEQ ID NO: 159 is Thr (T) or Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Leu (L) or Phe (F)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid
- the amino acid at position 6 of SEQ ID NO: 161 is Asn (N) or Ser
- S amino acid at position 10 of SEQ ID NO: 161 is Vai (V) or Phe (F).
- amino acid at position 3 of SEQ ID NO: 158 is Thr
- the amino acid at position 1 of SEQ ID NO: 159 is Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Leu (L) or Phe (F)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid (preferably Ala (A), Vai (V), Leu (L), He (I), Pro (P), Phe (F), or Met (M))
- the amino acid at position 6 of SEQ ID NO: 161 is Asn (N) or Ser (S)
- the amino acid at position 10 of SEQ ID NO: 161 is Vai (V).
- the amino acid at position 3 of SEQ ID NO: 158 is Thr (T) or He (I)
- the amino acid at position 1 of SEQ ID NO: 159 is Thr (T) or Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Leu (L)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid
- the amino acid at position 6 of SEQ ID NO: 161 is Asn (N)
- the amino acid at position 10 of SEQ ID NO: 161 is Phe (F) or Vai (V).
- the amino acid at position 3 of SEQ ID NO: 158 is Thr (T)
- the amino acid at position 1 of SEQ ID NO: 159 is Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Leu (L)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid (preferably Ala (A), Vai (V), Leu (L), lie (I), Pro (P), Phe (F), or Met (M))
- the amino acid at position 6 of SEQ ID NO: 161 is Asn (N)
- the amino acid at position 10 of SEQ ID NO: 161 is Vai (V).
- the amino acid at position 3 of SEQ ID NO: 158 is He (I)
- the amino acid at position 1 of SEQ ID NO: 159 is Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Phe (F)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid
- the amino acid at position 6 of SEQ ID NO: 161 is Ser (S)
- the amino acid at position 10 of SEQ ID NO: 161 is Vai (V).
- the amino acid at position 3 of SEQ ID NO: 158 is He (I)
- the amino acid at position 1 of SEQ ID NO: 159 is Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Phe (F)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid(preferably Ala (A), Vai (V), Leu (L), He (I), Pro (P), Phe (F), or Met (M))
- the amino acid at position 6 of SEQ ID NO: 161 is Ser (S)
- the amino acid at position 10 of SEQ ID NO: 161 is Vai (V).
- the disclosure provides an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, the isolated antibody, or the antigen-binding fragment thereof, comprising:
- a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 157, or an amino acid sequence at least 80% homologous thereto
- a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 160, or an amino acid sequence at least 80% homologous thereto (1212 variant); or a pharmaceutically acceptable form of any of the foregoing, such as, but not limited to a pharmaceutically acceptable salt, solvate and/or hydrate.
- the amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2A below and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2B below.
- the amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2C below and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2D below.
- the amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2E below and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2F below.
- the amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2G below and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2H below.
- the antibody is provided as a pharmaceutically acceptable salt.
- the antibodies bind an epitope within the RBD of the SARS-CoV-2 spike protein. In one aspect of any of the antibodies of the first to fourth embodiments, the antibodies bind an epitope within the RBM of the SARS-CoV-2 spike protein. In one aspect of any of the antibodies of the first to fourth embodiments, the antibodies bind an epitope within the SI region of the SARS-CoV-2 spike protein. In one aspect of any of the antibodies of the first to fourth embodiments, the antibodies bind an epitope within the S2 region of the SARS-CoV-2 spike protein.
- the antibodies reduce binding of SARS-CoV-2 to a target cell. In one aspect of any of the antibodies of the first to fourth embodiments, the antibodies reduce cellular fusion between SARS-CoV-2 and a target cell. In one aspect of any of the antibodies of the first to fourth embodiments, the antibodies reduce release of infective SARS-CoV-2 from an infected cell. In one aspect of any of the antibodies of the first to fourth embodiments, the antibodies reduce infection of a target cell by SARS-CoV-2.
- the antibody is an antibody variant. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is an antibody variant comprising one or more substitutions, deletions, and/or insertions relative to the parental antibody. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is an antibody variant comprising one or more substitutions relative to the parental antibody.
- the antibody is an antibody variant that has a longer half-life in vivo in a subject relative to the parental antibody, decreased immunogenicity in vivo in a subject relative to the parental antibody, or a combination of the foregoing.
- the antibody comprises a variant Fc constant region. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody comprises a variant Fc constant region, wherein a protein moiety or non-protein moiety is linked to the Fc constant region. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody comprises a variant Fc constant region, wherein a water soluble polymer is linked to the Fc constant region. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody comprises a variant Fc constant region, wherein a polyethylene glycol polymer is linked to the Fc constant region.
- the antibody comprises a variant Fc constant region, wherein a polyoxazoline polymer is linked to the Fc constant region. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody comprises a variant Fc constant region, wherein the variant Fc constant region provides a longer half-life in vivo in a subject relative to the parental antibody, decreased immunogenicity in vivo in a subject relative to the parental antibody, or a combination of the foregoing.
- the antibody is a human antibody. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is a chimeric antibody. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is a cl ass- switched antibody.
- the antibody is linked to a therapeutic agent. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is linked to a detectable label. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is linked to an enzyme. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is linked to an enzyme inhibitor.
- the antibody is an antigen-binding fragment. In one aspect of any of the antibodies of the first to fourth embodiments, the antibody is an antigen-binding fragment selected from the groups consisting of: a Fab fragment, a F(ab)2 fragment, a Fab' fragment, a Fd fragment, a Fv fragment, a disulfide-linked Fv (sdFv), a dAb fragment, an isolated CDR, a nanobody or single domain antibody, a portion of the VH region containing a single variable domain and two constant domains, a diabody, a triabody, a tetrabody, scFv, scFv-FC, scFv-CH, scFab, and scFv-zipper.
- the amino acid sequence has at least 85% homology to the reference sequence, at least 90% homology to the reference sequence, at least 95% homology to the reference sequence, at least 96% homology to the reference sequence, at least 97% homology to the reference sequence, at least 98% homology to the reference sequence, or at least 99% homology to the reference sequence.
- the antibody is 100% homologous to the reference sequence across the CDRs and the amino acid sequence has at least 85% homology to the reference sequence across the FRs, the amino acid sequence has at least 85% homology to the reference sequence across the FRs, at least 90% homology to the reference sequence across the FRs, at least 95% homology to the reference sequence across the FRs, at least 96% homology to the reference sequence across the FRs, at least 97% homology to the reference sequence across the FRs, at least 98% homology to the reference sequence across the FRs, or at least 99% homology to the reference sequence across the FRs.
- an antibody of the disclosure is an antigen-binding fragment.
- Antigen-binding fragment include, but are not limited to, Fab, Fab', Fab'-SH, F(ab)2, F(ab’)2, Fv, Fd, sdFv, dAb scFv fragments (including, but not limited to, scFv-FC, scFv-CH, scFab, and scFv- zipper), diabodies, triabodies tetrabodies, nanobodies, and other fragments described here.
- Fab and F(ab) fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.
- Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells as described herein or as known in the art.
- an antibody of the disclosure is a chimeric antibody.
- a chimeric antibody comprises a non-human variable region (for example, a variable region derived from a mouse, rat, hamster, rabbit, or a monkey or other non-human primate) and a human constant region.
- a chimeric antibody is a “class switched” antibody in which the class or subclass of the antibody has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
- a chimeric antibody is a humanized chimeric antibody.
- an antibody of the disclosure is a human antibody.
- Human antibodies can be produced using various techniques known in the art or using techniques described herein. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008). Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes.
- Human antibodies can also be made by hybridoma-based methods.
- Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies are known in the art (Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991)).
- Human antibodies generated via human B-cell hybridoma technology are also known in the art (Li et al., Proc. Natl. Acad. Sci. USA, 103:3557- 3562 (2006)).
- Human antibodies may also be generated by 1 isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain.
- amino acid sequence variants of the antibodies provided herein are contemplated. Such variants may be used to improve the binding affinity of an antibody, to improve a biological property of an antibody (such as, but not limited to, half-life), or a combination of the foregoing.
- Amino acid variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis directly incorporating such amino acid change.
- Antibody variants include, but are not limited to, fusion proteins including an antibody of the disclosure, substitutions of one or more amino acids, deletion of one or more amino acids, insertion of one or more amino acids, and any combination of the foregoing. In certain embodiments, the antibody variant retains the ability to bind to the same epitope.
- antibody variants having one or more amino acid substitutions are provided.
- the substitution may be made at any desired location.
- the substitution occurs in the Sites of interest for substitutional mutagenesis include the VH region, the VL region, the heavy chain CDRs, the light chain CDRs, and/or the FR region. Such substitutions may be conservative or nonconservative. Conservative substitutions are defined herein.
- an antibody of the disclosure comprises a conservative amino acid substitution.
- such conservative amino acid substitution may be made in the VH region, the VL region, the heavy chain CDRs, the light chain CDRs, and/or the FR region.
- the disclosure provides for an antibody variant of one or more of the polypeptides of SEQ ID NOS: 37 to 156.
- the disclosure provides for an antibody variant comprising one or more substitutions, including conservative substitutions, of one or more of the polypeptides of SEQ ID NOS: 37 to 156.
- an antibody variant comprising one or more substitutions, including conservative substitutions, of the heavy chain variable region (including CDRs 1-3) and/or light chain variable region (including CDRs 1-3), of one or more of the polypeptides of SEQ ID NOS: 37 to 156.
- an antibody variant has an amino acid sequence that is at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a parent antibody.
- the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences.
- the percent identity between two amino acid sequences is preferably determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- an antibody variant includes a conservative modification.
- conservative modifications refers to an amino acid modification that does not significantly affect or alter the binding characteristics of the antibody containing the conservative modification. Such conservative modifications include amino acid substitutions, additions, and deletions.
- an antibody variant contains a conservative amino acid substitution.
- Conservative amino acid substitutions are ones in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include: amino acids with basic side chains (lysine, arginine, and histidine), acidic side chains (aspartic acid and glutamic acid), uncharged polar side chains (glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, and tryptophan), nonpolar side chains (alanine, valine, leucine, isoleucine, proline, phenylalanine, and methionine), beta-branched side chains (threonine, valine, and isoleucine), and aromatic side chains (tyrosine, phenylalanine, tryptophan, and histidine). Non-conservative substitutions will entail exchanging a member of one of these classes for
- a conservative amino acid substitution may involve a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity, steric bulk, charge, hydrophobicity and/or hydrophilicity of the amino acid residue at that position.
- Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties. It will be appreciated by those of skill in the art that polypeptide described herein may be chemically synthesized as well as produced by recombinant means.
- the hydropathic index of an amino acid may be considered.
- Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics. Hydropathic index values are resented by: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cy stine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
- hydropathic amino acid index in conferring interactive biological function on a protein is understood in the art (Kyte et al., J. Mol. Biol. 157: 105-131, 1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In one embodiment, making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within +/- 1; in an alternate embodiment, the hydropathic indices are within +/- 0.5; in yet another alternate embodiment, the hydropathic indices are within +/- 0.25.
- the hydrophilicity may also be considered.
- the greatest local average hydrophilicity of a polypeptide as governed by the hydrophilicity of its adjacent amino acids correlates with a biological property of the protein.
- hydrophilic index values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0.+-.1); glutamate (+3.0.+-.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5.+-.1); alanine (- 0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (- 1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).
- a skilled artisan will be able to determine suitable substitutions, insertions and deletions, including combinations thereof, of a polypeptide as set forth in any of SEQ ID NOS: 37 to 156 using techniques known in the art. For identifying suitable areas of a polypeptide that may be changed without destroying activity, one skilled in the art may target areas not believed to be important for activity.
- homologous polypeptides with similar activities from the same species or from other species are known, one skilled in the art may compare the amino acid sequence of a polypeptide described herein to such homologous polypeptides. With such a comparison, one can identify residues and portions of the molecules that are conserved among similar polypeptides. It will be appreciated that changes in areas of a polypeptide described herein that are not conserved relative to such homologous polypeptide would be less likely to adversely affect the biological activity and/or structure of a polypeptide described herein. One skilled in the art would also know that, even in relatively conserved regions, one may substitute chemically similar amino acids for the naturally occurring residues while retaining activity (for example, conservative amino acid substitutions). Therefore, even areas that may be important for biological activity or for structure may be subject to such amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.
- deletions, insertions, and substitutions can be selected, as would be known to one of ordinary skill in the art, to generate a desired polypeptide variants. For example, it is not expected that deletions, insertions, and substitutions in a non-functional region of a polypeptide would alter activity. Likewise conservative amino acid substitutions and/or substitution of amino acids with similar hydrophilic and/or hydropathic index values is expected to be tolerated in a conserved region and a polypeptide activity may be conserved with such substitutions.
- An exemplary substitution variant is an affinity matured antibody, which may be conveniently generated using phage display-based affinity maturation techniques such as those described in Hoogenboom et al., in Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., (2001)).
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intra-sequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue.
- insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme or a polypeptide which increases the serum half-life of the antibody.
- An antibody variant may be screened for a desired activity, including, but not limited to, retained epitope binding, improved epitope binding, decreased immunogenicity, improved antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) or any combination of the foregoing.
- a non-protein based moiety is a polymer, preferable a water soluble polymer.
- Suitable water soluble polymers include, but are not limited to, polyethylene glycol (PEG), polyoxazoline (POZ), carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1, 3, 6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either as a homopolymer or a copolymer), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol, poly oxy ethylated polyols (such as glycerol), polyvinyl alcohol, copolymers of ethylene glycol and propylene glycol, copolymers of propylene glycol, copolymers of propylene glycol, copolymers of ethylene glycol and propy
- the copolymer may be present as a block copolymer or a random copolymer.
- An amino acid substitution may be used to introduce a site for attachment of a water soluble polymer to the antibody.
- the water soluble polymer may be of any molecular weight, and may be dendrimers, branched or unbranched.
- the number of polymers attached to an antibody may vary.
- the number average molecular weight of the water soluble polymer is from 2,500 to 75,000 Da, from 5,000 to 50,000 Da, from 7,500 to 40,000 Da, or from 10,000 to 30,000 Da.
- 1 to 10 water soluble polymer chains are attached.
- the water soluble polymers may be the same or different and may be of the same of different number average molecular weight.
- the water soluble polymers increases the half-life of an antibody of the disclosure and/or decrease immunogenicity of an antibody of the disclosure.
- Water soluble polymers may be linked to an antibody of the disclosure using conventional reactive groups on the polymer and the antibody.
- water soluble polymers such as. But not limited to, POZ and PEG polymers, may be linked to an antibody using acylation alkylation reactions.
- Water soluble polymers may be linked to the antibody in a site specific manner or randomly (for example, the e-amino group of a lysine residue or the thiol group of cysteine residue may be used in conjugation reactions with an appropriate functionality on the water soluble polymer).
- a non-natural amino acid may be introduced into the antibody and used to link a water soluble polymer to the antibody.
- a selenocysteine residue may be introduced into the antibody for reaction with a water soluble polymer containing an appropriate functionality (for example, a maleimide group or an iodoacetimide group).
- the water soluble polymer may be linked to a therapeutic agent, a detectable label, an enzyme, or an enzyme inhibitor as described herein.
- a non-protein based moiety is a therapeutic agent, for example a therapeutic agent useful in treating a SARS-CoV-2 infection as described herein or a cytotoxic agent.
- a non-protein based moiety is a detectable label.
- a non-protein based moiety is an enzyme.
- a non-protein based moiety is an enzyme inhibitor, for example a serine protease inhibitor, such as, but not limited to, a TMPRSS2 inhibitor.
- an antibody of the disclosure is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.
- an aglycoslated antibody can be made. Glycosylation can be altered to for a variety of purposes, including, but not limited to, to increase the affinity of the antibody for an antigen.
- one or more amino acid substitutions are made that result in elimination of one or more FR glycosylation sites, which may increase the affinity of the antibody for antigen. Such an approach is described in further detail in U.S. Pat. Nos. 5,714,350 and 6,350,861.
- N297 in the Fc portion may be substituted with another residue (for example, alanine) and/or by mutating an adjacent amino acid to thereby reduce glycosylation on N297.
- N297 in the Fc portion may be substituted with another residue (for example, alanine) and/or by mutating an adjacent amino acid to thereby reduce glycosylation on N297.
- an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures.
- altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies.
- carbohydrate modifications can be accomplished, for example, by expressing the antibody in a host cell with altered glycosylation machinery (such cells are described in EP 1,176,195; PCT Publication WO 03/035835; Shields, R. L. et al. (2002), J. Biol. Chem. 277:26733-26740; PCT Publication WO 99/54342; Umana et al. (1999), Nat. Biotech. 17: 176-180).
- variable regions of the antibody described herein can be linked to an Fc region (such as, but not limited to, an IgGl, IgG2, IgG3 or IgG4 Fc), which may be of any allotype or isoallotype (including for IgGl : Glm, Glml(a), Glm2(x), Glm3(f), Glml7(z); for IgG2: G2m, G2m23(n); for IgG3: G3m, G3m21(gl), G3m28(g5), G3ml l(b0), G3m5(bl), G3ml3(b3), G3ml4(b4), G3ml0(b5), G3ml5(s), G3ml6(t), G3m6(c3), G3m24
- an Fc region such as, but not limited to, an IgGl, IgG2, IgG3 or IgG4 Fc
- variable regions of the antibodies described herein are linked to an Fc that binds to one or more activating Fc receptors (FcR), and thereby stimulate ADCC.
- the variable regions of the antibodies described herein are linked to an Fc region optimized to engage a wider range of Fc receptors.
- Fc receptors for isotypes other than gamma exist on particular leukocytes. By creating an Fc region that can interact with multiple Fc receptors, such as FcyRI and FcaRI, an antibody with expanded, novel abilities to engage effector cells may be created. Neutrophils are the most abundant leukocyte in the body and engage Fc of IgA antibodies via the FcaRI.
- the antibody variable regions described herein may be linked to an Fc comprising one or more modification, typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, ADCC, and/or CDC.
- the Fc region encompasses domains derived from the constant region of an antibody.
- Suitable immunoglobulins include IgG 1, IgG2, IgG3, IgG4, IgAl, IgA2, and other classes such as IgD, IgE and IgM
- the constant region of an antibody is defined as a naturally-occurring or synthetically-produced polypeptide homologous to the antibody C-terminal region, and can include a CHI domain, a hinge, a CH2 domain, a CH3 domain, or a CH4 domain, separately or in combination.
- an antibody of the disclosure has an Fc region other than that of a wild type IgAl.
- An antibody of the disclosure may have an Fc region from that of IgG (e.g., IgGl, IgG2, IgG3, and IgG4) or other classes such as IgA2, IgD, IgE and IgM.
- An antibody of the disclosure may have an Fc region that is contains a substitution, deletion, or insertion of wild-type IgAl.
- the Fc of an antibody is responsible for many important functions including FcR binding and complement fixation.
- the serum half-life of an antibody is influenced by the ability of that antibody to bind to an FcR.
- Antibody molecules interact with multiple classes of cellular receptors.
- IgG molecules interact with three classes of FcyR specific for the IgG class of antibody, namely FcyRI, FcyRIIa, FcyRIIb, FcyRIIIa, and FcyRIIIb.
- FcyRI FcyRI
- FcyRIIa FcyRIIa
- FcyRIIb FcyRIIb
- FcyRIIIa FcyRIIIb
- the Fc region is a variant Fc region (an Fc sequence that has been modified such as by amino acid substitution, deletion and/or insertion) relative to a parent Fc sequence to provide desirable structural features and/or biological activity, including, but not limited to, (i) increased or decreased ADCC; (ii) increased or decreased CDC; (iii) increased or decreased affinity for Clq; and/or (iv) increased or decreased affinity for a FcR (each of the foregoing relative to the parent Fc).
- Such Fc region variants will generally comprise at least one amino acid substitution, deletion, and/or insertion in the Fc region.
- an Fc region contains from 1 to 6 amino acid substitutions, deletions and/or insertions (preferably substitutions).
- a variant Fc region may also comprise a sequence modification wherein an amino acid involved in disulfide bond formation are removed or replaced with another amino acid.
- the Fc region may be modified to make it more compatible with a selected host cell. For example, one may remove the PA sequence near the N-terminus of a typical native Fc region, which may be recognized by a digestive enzyme in E. coli such as proline iminopeptidase.
- one or more glycosylation sites within the Fc domain are removed. Residues that are typically glycosylated (e.g., asparagine) may confer cytolytic response. Such residues may be deleted or substituted with unglycosylated residues e.g., alanine).
- sites involved in interaction with complement may be removed from the Fc region.
- sites involved in interaction with complement such as the Clq binding site
- sites that affect binding to Fc receptors may be removed, preferably sites other than salvage receptor binding sites.
- an Fc region may be modified to remove an ADCC site known in the art. Specific examples of variant Fc domains are disclosed for example, in WO 1997/34631 and WO 1996/32478.
- the hinge region of Fc is modified such that the number of cysteine residues in the hinge region is increased or decreased (U.S. Pat. No. 5,677,425) to, for example, facilitate assembly of the light and heavy chains and/or to increase or decrease the stability of the antibody.
- the Fc hinge region of an antibody is mutated to decrease the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge fragment such that the antibody has impaired Staphylococcal protein A (SpA) binding relative to native Fc-hinge domain SpA binding (U.S. Pat. No. 6,165,745).
- SpA Staphylococcal protein A
- the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter an effector function of the antibody.
- one or more amino acids selected from amino acid residues 234, 235, 236, 237, 297, 318, 320 and 322 can be replaced with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigen-binding ability of the parent antibody.
- the effector ligand to which affinity is altered can be, for example, an FcR or the CI component of complement (U.S. Pat. Nos. 5,624,821 and 5,648,260).
- one or more amino acids selected from amino acid residues 329, 331 and 322 can be replaced with a different amino acid residue such that the antibody has altered Clq binding and/or reduced or abolished CDC (U.S. Pat. No. 6,194).
- one or more amino acid residues within amino acid positions 231 and 239 are altered to thereby alter the ability of the antibody to fix complement (PCT Publication WO 1994/29351). All references to Fc region amino acid numbering is made according to the EU index of Kabat (Kabat et al., (1983) "Sequences of Proteins of Immunological Interest", US Dept. Health and Human Services).
- the Fc region may be modified to increase ADCC and/or to increase the affinity for an FcyR by modifying one or more amino acids at the following positions: 234, 235, 236, 238, 239, 240, 241, 243, 244, 245, 247, 248, 249, 252, 254, 255, 256, 258, 262, 263,
- substitutions include 236A, 239D, 239E, 268D, 267E, 268E, 268F, 324T, 332D, and 332E.
- Exemplary variants include 239D/332E, 236A/332E, 236A/239D/332E, 268F/324T, 267E/268F, 267E/324T, and 267E/268F7324T.
- Fc modifications that increase binding to an FcyR include amino acid modifications at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 279, 280, 283, 285, 298, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 312, 315, 324, 327, 329, 330, 335, 337, 3338, 340, 360, 373, 376, 379, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or 439 of the Fc region.
- Fc modifications that can be made are those for reducing or ablating binding to FcyR and/or complement proteins, thereby reducing or ablating Fc-mediated effector functions such as ADCC, ADCP, and CDC.
- Exemplary modifications include but are not limited substitutions, insertions, and deletions at positions 234, 235, 236, 237, 267, 269, 325, and 328, wherein numbering is according to the EU index of Kabat.
- Exemplary substitutions include but are not limited to 234G, 235G, 236R, 237K, 267R, 269R, 325L, and 328R, wherein numbering is according to the EU index of Kabat.
- An Fc variant may comprise 236R/328R.
- the Fc region may comprise a non-naturally occurring amino acid residue at additional and/or alternative positions known to one skilled in the art (U.S. Pat. Nos. 5,624,821; 6,277,375; 6,737,056; 6,194,551; 7,317,091; 8,101,720; PCT Publication Nos: WO 2000/42072; WO 2001/58957; WO 2002/06919; WO 2004/016750; WO 2004/029207; WO 2004/035752; WO 2004/074455; WO 2004/099249; WO 2004/063351; WO 2005/070963; WO 2005/040217, WO 2005/092925 and WO 2006/020114).
- Fc variants that enhance affinity for an inhibitory receptor FcyRIIb may also be used. Such variants may provide an Fc fusion protein with immune-modulatory activities related to FcyRIIb cells, including for example B cells and monocytes. In one embodiment, the Fc variants provide selectively enhanced affinity to FcyRIIb relative to one or more activating receptors. Modifications for altering binding to FcyRIIb include one or more modifications at a position selected from the group consisting of 234, 235, 236, 237, 239, 266, 267, 268, 325, 326, 327, 328, and 332, according to the EU index of Kabat.
- Exemplary substitutions for enhancing FcyRIIb affinity include but are not limited to 234D, 234E, 234F, 234W, 235D, 235F, 235R, 235Y, 236D, 236N, 237D, 237N, 239D, 239E, 266M, 267D, 267E, 268D, 268E, 327D, 327E, 328F, 328W, 328Y, and 332E.
- Exemplary substitutions include 235Y, 236D, 239D, 266M, 267E, 268D, 268E, 328F, 328W, and 328Y.
- Fc variants for enhancing binding to FcyRIIb include 235Y/267E, 236D/267E, 239D/268D, 239D/267E, 267E/268D, 267E/268E, and 267E/328F.
- the affinities and binding properties of an Fc region for its ligand may be determined by a variety of in vitro assay methods (biochemical or immunological based assays) known in the art including but not limited to, equilibrium methods (enzyme-linked immune-absorbent assay, radioimmunoassay, or kinetics, and other methods such as indirect binding assays, competitive inhibition assays, fluorescence resonance energy transfer, gel electrophoresis and chromatography). These and other methods may utilize a label on one or more of the components being examined and/or employ a variety of detection methods including but not limited to chromogenic, fluorescent, luminescent, or isotopic labels.
- a detailed description of binding affinities and kinetics can be found in Paul, W. E., ed., Fundamental immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999), which focuses on antibody -immunogen interactions.
- the antibody is modified to increase its biological half-life.
- this may be done by increasing the binding affinity of the Fc region for FcRn.
- one or more of following residues can be mutated: 252, 254, 256, 433, 435, and 436, as described in U.S. Pat. No. 6,277,375.
- Specific exemplary substitutions include one or more of the following: T252L, T254S, and/or T256F.
- the antibody can be altered within the CHI or CL region to contain a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG, as described in U.S. Pat. Nos.
- variants that increase binding to FcRn and/or improve pharmacokinetic properties include substitutions at positions 259, 308, 428, and 434, including for example 2591, 308F, 428L, 428M, 434S, 434H. 434F, 434Y, and 434M.
- Other variants that increase Fc binding to FcRn include: 250E, 250Q, 428L, 428F, 250Q/428L (Hinton et al. 2004, J. Biol. Chem. 279(8): 6213-6216, Hinton et al.
- hybrid IgG isotypes with particular biological characteristics may be used.
- an IgGl/IgG3 hybrid variant may be constructed by substituting IgGl positions in the CH2 and/or CH3 region with the amino acids from IgG3 at positions where the two isotypes differ.
- a hybrid variant IgG antibody may be constructed that comprises one or more substitutions, e.g., 274Q, 276K, 300F, 339T, 356E, 358M, 384S, 392N, 397M, 4221, 435R, and 436F.
- an IgGl/IgG2 hybrid variant may be constructed by substituting IgG2 positions in the CH2 and/or CH3 region with amino acids from IgGl at positions where the two isotypes differ.
- a hybrid variant IgG antibody may be constructed chat comprises one or more substitutions, e.g., one or more of the following amino acid substitutions: 233E, 234L, 235L, 236G (referring to an insertion of a glycine at position 236), and 321 h.
- IgGl variants with strongly enhanced binding to FcyRIIIa have been identified, including variants with S239D/I332E and S239D/I332E/A330L mutations which showed the greatest increase in affinity for FcyRIIIa, a decrease in FcyRIIb binding, and strong cytotoxic activity in cynomolgus monkeys (Lazar et al., 2006).
- IgGl mutants containing L235V, F243L, R292P, Y300L and P396L mutations which exhibited enhanced binding to FcyRIIIa and concomitantly enhanced ADCC activity in transgenic mice expressing human FcyRIIIa in models of B cell malignancies and breast cancer have been identified (Stavenhagen et al., 2007; Nordstrom et al., 2011).
- Other Fc mutants that may be used include, but are not limited to: S298A/E333A/L334A, S239D/I332E, S239D/I332E/A330L,
- an Fc is chosen that has reduced binding to FcyRs.
- An exemplary Fc, e.g., IgGl Fc, with reduced FcyR binding comprises the following three amino acid substitutions: L234A, L235E and G237A.
- an Fc is chosen that has reduced complement fixation.
- An exemplary Fc e.g., IgGl Fc, with reduced complement fixation has the following two amino acid substitutions: A33OS and P331S.
- an Fc is chosen that has essentially no effector function, i.e., it has reduced binding to FcyRs and reduced complement fixation.
- An exemplary Fc, IgGl Fc that is effectorless comprises the following five mutations: L234A, L235E, G237A, A33OS and P331S.
- substitution S228P which mimics the hinge sequence in IgGl and thereby stabilizes IgG4 molecules.
- the disclosure also provides for nucleic acid sequences encoding the antibodies of the disclosure.
- the nucleic acid sequences may code for an antigen-binding fragment.
- the nucleic acids are codon optimized based on how the antibodies are produced.
- the nucleic acid sequence comprises one or more of SEQ ID NOS: 1 to 36.
- the nucleic acid sequence has at least 75% homology, at least 80% homology, at least 85% homology, at least 90% homology, at least 95% homology, or greater than 95% homology with one or more of SEQ ID NOS: 1 to 36.
- the disclosure also provides a vector comprising a nucleic acid sequence coding for an antibody of the disclosure.
- a vector comprises a nucleic acid sequence coding for a variable heavy chain region and a nucleic acid sequence coding for a variable light chain region. Any nucleic acid sequence of the disclosure (SEQ ID NOS: 1-36) may be combined with a vector as described herein.
- a nucleic acid sequence coding for a variable heavy chain is on the same vector as a nucleic acid sequence coding for a variable light chain.
- a nucleic acid sequence coding for a variable heavy chain region is on a different vector than a nucleic acid sequence coding for a variable light chain region.
- the vector is a plasmid. In some embodiments, the vector is a phage vector, such as, but not limited to, X-phage. In some embodiments, the vector is a viral vector, such as, but not limited to, non-replicating adenoviral vector, lentiviral vector, pSV, pCMV, and retroviral vectors. In some embodiments, the vector is a cosmid. In some embodiments, the vector is a recombinant chromosome. In some embodiments, the combinations of the foregoing vectors are employed. The expression of different nucleic acid sequences may occur at the same time generally or be temporally separated. The expression of one or more nucleic acid sequences may be inducible.
- the vector may comprise a nucleic acid coding for an intact antibody or an antigen binding fragment, particularly those antigen-binding fragments disclosed herein.
- the vector comprises a nucleic acid sequence encoding an immunoglobulin constant region, such as, but not limited to, an IgG (e.g. IgGl, IgG2, IgG3, and IgG4) constant region.
- an immunoglobulin constant region comprises an IgGl constant region.
- the disclosure provides for a vector comprising nucleotide sequences that code for the heavy and/or light chain variable regions of an antibody selected from the groups consisting of 1212C2, 1212F5, 1213H7, 1212F2, 1206D1, 1212D5, 1207B4, 1213F2, 1212D4, 1206A5, 1212D6, 1206D12, 1207F10, 1206G12, 1212C8, 1212E9, 1214E9, and 1215D1.
- the vector may be a mammalian expression vectors, such that the vector may be transfected into mammalian cells and the DNA may be integrated into the genome by homologous recombination in the case of stable transfection, or alternatively the cells may be transiently transfected.
- Common to most engineered vectors are origin of replications, multicloning sites, and selectable markers.
- Common promoters for mammalian expression vectors include CMV and SV40 promoters, and non-viral promoters such as, but not limited to, EF-1 promoters.
- the disclosure provides a vector comprising one or more nucleic acid sequences encoding one or more CDRs of one or more heavy and/or light chains of one or more of the antibodies of the disclosure (for example, a nucleic acid encoding an amino acid sequences of SEQ ID NOS: 38-40, 42-44, 46- 48, 50-52, 54-56, 58-60, 62-64, 66-68, 70-72, 74-76, 78-80, 82-84, 86-88, 90-92, 94-96, 98- 100102-104, 106-108, 110-112, 114-116, 118-120, 122-124, 126-128, 130-132, 134-135, 138- 140, 142-144, and 146-148, or an amino acid having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or greater than 95% homology with SEQ ID NOS: 38-40, 42-44, 46-48, 50-
- the disclosure provides a vector comprising one or more nucleic acid sequences encoding one or more heavy and/or light chain variable regions of one or more of the antibodies of the disclosure (for example, a nucleic acid encoding an amino acid sequences of SEQ ID NOS: 37, 42, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101,
- the nucleic acid sequences may encode for an antibody variant as described herein, including an antibody containing a conservative substitution.
- a vector that codes for one or both variable region(s) of an antibody of the disclosure may contain one of or both of SEQ ID NOS: required to generate such antibody, or a nucleotide sequence that shares a degree minimum of homology with such SEQ ID NOS: (for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more than 95% homology).
- a vector that encodes the heavy and light chain variable region of antibody 1212C2 may comprise SEQ ID NOS: 1 and 2, or a nucleotide sequence that shares a degree minimum of homology with such SEQ ID NOS: 1 and 2 (for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more than 95% homology).
- the disclosure also provides for a cell transformed with a vector described herein.
- a cell transformed with a vector described herein may lead to different antibody products and may possibly impact the therapeutic efficacy of the antibody products, e.g. through having distinct variations in glycosylation patterns, especially N-linked glycosylation patterns.
- Such discussions may be found in Liu L, J Pharm Sci. 2015 June; 104(6): 1866-84; Rosenlocher et al., J Proteomics. 2016 Feb. 16; 134:85-92; Mimura et al., J Immunol Methods. 2016 January; 428:30-6; and Croset et al., Journal of Biotechnology, 161(3), Oct. 31, 2012.
- the cell is a bacterial cell, a yeast cell, a plant cell, or a mammalian cell.
- the mammalian cell is one of a Chinese hamster ovary (CHO) cell, including DUXB11, DG44 and CHOK1 lineages, a NSO murine myeloma cell, aPER.C6 cell, and a human embryonic kidney (HEK) cell, including HEK293 lineages.
- CHO Chinese hamster ovary
- HEK human embryonic kidney
- Other less common host cells include plant cells, for example, those based on the tumor-inducing (Ti) plasmid of Agrobacterium tumefaciens.
- Cell-free expression systems also exist, for example, based on E.
- Eukaryotic and mammalian cell-free systems are also known in the art, for example wheat germ cell-free expression system. Some recombinant antibody production systems express the recombinant antibodies on the surface of the host cell before harvesting, others simply release the antibodies into a medium for collection. Such variations are intended to be within the scope of the disclosure.
- the disclosure also provides for a method of making a recombinant antibody of the disclosure.
- the antibody is an antigen binding fragment.
- the host cell comprising a vector described herein is induced to produce the recombinant antibodies and the host cell assembles the antibodies from heavy/light chains in the host cell and then transport the antibodies out of the cell, or the antibodies may self-assemble outside the host cell and be exported as heavy/light chains.
- An overview of cell culture processes for recombinant monoclonal antibody production may be found in Li et al., Mabs. 2010 September-October; 2(5): 466-477.
- the disclosure provides for a method of making a recombinant antibody, or antigenbinding fragment thereof, that specifically binds to SARS-CoV-2 spike protein, the method comprising providing a cell comprising a vector comprising a nucleic acid sequence encoding a heavy chain variable region and/or a light chain variable region of any one of SEQ ID NOS: 1-36, expressing at least one nucleic acid sequence in the vector to create at least one of a heavy chain, a light chain, or combinations thereof, and collecting a formed antibody or the antigen-binding fragment, thereof.
- Antibodies of the disclosure may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics (Hoogenboom et al. in Methods in Molecular Biology 178: 1- 37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001); McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol.
- repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage.
- Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
- scFv single-chain Fv
- Fab fragments fragments from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas.
- the naive repertoire can be cloned (e.
- naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro (Hoogenboom and Winter, I. Mol. Biol., 227: 381-388 (1992)).
- Antibodies, including antigen-binding fragments, isolated from human antibody libraries are considered human antibodies.
- the disclosure provides a method for treating a SARS-CoV-2 infection in a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2 either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- a combination of 1212C2 and 1213H7 mAbs are used.
- the disclosure provides a method for suppressing a SARS-CoV-2 infection in a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the disclosure provides a method for preventing a SARS-CoV-2 infection in a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the disclosure provides a method for treating, suppressing and/or preventing a disease or condition relating to a SARS-CoV-2 infection in a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the disease or condition is Guillain- Barre Syndrome.
- the disease or condition is multisystem inflammatory syndrome, particularly when the subject is under the age of 25 years of age.
- the disease or condition is organ injury, such as, but not limited to, lung injury, liver injury, and/or heart injury. In certain embodiments of the fourth aspect, the disease or condition is acute respiratory distress syndrome. In certain embodiments of the fourth aspect, the disease or condition is increased inflammation resulting from an imbalance in the renin-angiotensin system (such as, but not limited to, excess production of angiotensin II and/or the decreased production of angiotensin 1-7).
- organ injury such as, but not limited to, lung injury, liver injury, and/or heart injury.
- the disease or condition is acute respiratory distress syndrome.
- the disease or condition is increased inflammation resulting from an imbalance in the renin-angiotensin system (such as, but not limited to, excess production of angiotensin II and/or the decreased production of angiotensin 1-7).
- the disclosure provides a method of reducing or preventing cellular entry of SARS-CoV-2 in a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, or a combination of the foregoing, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the disclosure provides a method of reducing or preventing binding of SARS-CoV-2 to a cellular ACE2 in a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the disclosure provides a method for reducing viral titer of a SARS- CoV-2 in a bodily fluid, tissue or cell of a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the transmission of the SARS-CoV-2 (for example, from a subject infected with SARS-CoV-2 to a subject that is not yet infected) is reduced as a result of a reduced viral titer.
- the disclosure provides a method for reducing or preventing the transmission of a SARS-CoV-2 infection from a first subject to a second subject, the method comprising administering to said first subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- such reduction or prevention is obtained, at least in part, by reducing the cellular entry of a SARS-CoV-2 in the first subject.
- administration to the first subject occurs before the first subject has been infected with SARS-CoV-2, after the first subject has been infected with the SARS-CoV-2, or after the first subject has been infected with the SARS-CoV-2 and before the SARS-CoV-2 infection can be detected.
- the disclosure provides a method for reducing or preventing the transmission of a SARS-CoV-2 infection from a first subject to a second subject, the method comprising administering to the second subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV- 2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the second subject may be at risk for SARS-CoV-2 infection.
- such reduction or prevention is obtained, at least in part, by preventing or reducing SARS-CoV-2 cellular entry in the second subject.
- such reduction or prevention is obtained, at least in part, by preventing or suppressing a SARS-CoV-2 infection in the second subject.
- a SARS-CoV-2 infection occurs in the second subject, it can be eliminated physiologically (for example, by the immune system) by the second subject, either with or without the administration of additional therapeutic compounds.
- administration to the second subject before the second subject has been infected with the SARS-CoV-2, after the second subject has been infected with the SARS-CoV-2, or after the second subject has been infected with the SARS-CoV-2 and before the SARS-CoV-2 infection can be detected.
- the disclosure provides a method of neutralizing a SARS-CoV-2 in a subject, the method comprising administering to said subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that specifically binds to the spike protein of SARS-CoV-2, either alone, combined with one or more other antibodies, and/or as a part of a pharmaceutical composition.
- the antibody, or an antigen-binding fragment thereof binds to SARS-CoV-2 viral particles before they are able to interact with cellular ACE2, thereby reducing or preventing SARS-CoV-2 viral particles from entering the cell.
- the antibody, or an antigen-binding fragment thereof reduces or prevents SARS-CoV-2 viral particles from binding to cellular ACE2.
- the antibody, or an antigen-binding fragment thereof reduces cleavage of the SARS-CoV-2 spike protein.
- the antibody, or an antigen-binding fragment thereof reduce binding of SARS-CoV-2 to a target cell. In certain embodiments of the methods of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, reduces cellular fusion between SARS-CoV-2 and a target cell. In certain embodiments of the methods of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, reduces release of infective SARS-CoV-2 from an infected cell. In certain embodiments of the methods of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, reduce infection of a target cell by SARS-CoV-2.
- the methods of the first to tenth aspects may further comprise one or more of the steps: i) identifying a subject in need or treatment, prevention, suppression, reduction, or inhibition; and (ii) providing an antibody, or an antigen-binding fragment thereof, of the disclosure or a pharmaceutical composition comprising the foregoing.
- the antibody or antibodies, or an antigen-binding fragment(s) thereof is any one or more antibodies or antigen binding fragment(s) described herein, or a pharmaceutically acceptable form thereof.
- the antibody or antibodies, or an antigen-binding fragment(s) thereof comprises:
- a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 102-104, respectively, and (ii) a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 106-108, respectively (1212D4);
- a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 126-128, respectively, and
- a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 130-132, respectively (1206D12);
- a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 142-144, respectively, and
- a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 146-148, respectively (1206G12), or a pharmaceutically acceptable form of any of the foregoing.
- the antibody, or an antigen-binding fragment thereof comprises:
- a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 101, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 105, or an amino acid sequence at least 80% homologous thereto (1212D4); (i) a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 109, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 113, or an amino acid sequence at least 80% homologous thereto (1206 A5); (i) a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 117, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 121, or an amino acid sequence at least 80% homologous thereto (1212D4);
- a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 155, or an amino acid sequence at least 80% homologous thereto
- a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 156 (1212C8), or an amino acid sequence at least 80% homologous thereto, or a pharmaceutically acceptable form of any of the foregoing.
- the antibody, or an antigen-binding fragment thereof comprises: (i) a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOS: 158, 39 and 159, respectively, and (ii) a light chain variable region that comprises LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOS: 42, 43, and 161, respectively (1212 variant), or a pharmaceutically acceptable form of any of the foregoing, such as, but not limited to a pharmaceutically acceptable salt, solvate and/or hydrate.
- the amino acid at position 1 of SEQ ID NO: 158 is Thr (T) or He (I)
- the amino acid at position 1 of SEQ ID NO: 159 is Thr (T) or Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Leu (L) or Phe (F)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid
- the amino acid at position 6 of SEQ ID NO: 161 is Asn (N) or Ser
- S amino acid at position 10 of SEQ ID NO: 161 is Vai (V) or Phe (F).
- amino acid at position 1 of SEQ ID NO: 158 is Thr
- the amino acid at position 1 of SEQ ID NO: 159 is Ala (A)
- the amino acid at position 9 of SEQ ID NO: 159 is Leu (L) or Phe (F)
- the amino acid at position 1 of SEQ ID NO: 161 is any amino acid (preferably Ala (A))
- the amino acid at position 6 of SEQ ID NO: 161 is Asn (N) or Ser (S)
- the amino acid at position 10 of SEQ ID NO: 161 is Vai (V).
- the amino acid at position 1 of SEQ ID NO: 158 is Thr (T)
- the amino acids at positions 1 and 9 of SEQ ID NO: 159 are Thr (T) and Leu (L), respectively
- the amino acids at positions 1, 6, and 10 of SEQ ID NO: 161 are any amino acid, Asn (N), and Phe (F), respectively.
- the amino acid at position 1 of SEQ ID NO: 158 is Thr (T)
- the amino acids at positions 1 and 9 of SEQ ID NO: 159 are Ala (A) and Leu (L), respectively
- the amino acids at positions 1, 6, and 10 of SEQ ID NO: 161 are any amino acid (preferably Ala (A)), Asn (N), and Vai (V), respectively.
- the amino acid at position 1 of SEQ ID NO: 158 is lie (I)
- the amino acids at positions 1 and 9 of SEQ ID NO: 159 are Ala (A) and Phe (F), respectively
- the amino acids at positions 1, 6, and 10 of SEQ ID NO: 161 are any amino acid, Ser (S), and Vai (V), respectively.
- the amino acid at position 1 of SEQ ID NO: 158 is lie (I)
- the amino acids at positions 1 and 9 of SEQ ID NO: 159 are Ala (A) and Phe (F), respectively
- the amino acids at positions 1, 6, and 10 of SEQ ID NO: 161 are any amino acid (preferably Ala (A)), Ser (S), and Vai (V), respectively.
- the antibody, or an antigen-binding fragment thereof comprises: (i) a heavy chain variable region that comprises the amino acid sequences of SEQ ID NO: 157, or an amino acid sequence at least 80% homologous thereto, and (ii) a light chain variable region that comprises the amino acid sequences of SEQ ID NO: 160, or an amino acid sequence at least 80% homologous thereto (1212 variant); or a pharmaceutically acceptable form of any of the foregoing, such as, but not limited to a pharmaceutically acceptable salt, solvate and/or hydrate.
- amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2A and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2B.
- amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2C and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2D.
- amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2E and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2F.
- the amino acids at positions 13, 23, 28, 59, 65, 77, 79, 94, 97, 105, and 113 of SEQ ID NO: 157 are selected from Table 2G below and the amino acids at positions 1, 2, 3, 91, 96, and 100 of SEQ ID NO: 160 are selected from Table 2H below.
- the antibody, or an antigen-binding fragment thereof comprises a mixture of any of the foregoing.
- the antibody, or an antigen-binding fragment thereof is present as a pharmaceutically acceptable salt.
- the antibody, or an antigen-binding fragment thereof binds an epitope within the RBD of the SARS-CoV-2 spike protein. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, binds an epitope within the RBM of the SARS-CoV-2 spike protein. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, binds an epitope within the S 1 region of the SARS-CoV-2 spike protein. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, binds an epitope within the S2 region of the SARS-CoV-2 spike protein.
- the antibody, or an antigen-binding fragment thereof reduces binding of SARS-CoV-2 to a target cell. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, reduces cellular fusion between SARS-CoV-2 and a target cell. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, reduces release of infective SARS-CoV-2 from an infected cell. In certain embodiments of the first to tenth aspects, the antibody, or an antigenbinding fragment thereof, reduces infection of a target cell by SARS-CoV-2.
- the antibody, or an antigen-binding fragment thereof is an antibody variant. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, is an antibody variant comprising one or more substitutions, deletions, and/or insertions relative to the parental antibody. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, is an antibody variant comprising one or more substitutions relative to the parental antibody.
- the antibody, or an antigen-binding fragment thereof is an antibody variant that has a longer half-life in vivo in a subject relative to the parental antibody, decreased immunogenicity in vivo in a subject relative to the parental antibody, or a combination of the foregoing.
- the antibody, or an antigen-binding fragment thereof comprises a variant Fc constant region. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, comprises a variant Fc constant region, wherein a protein moiety or non-protein moiety is linked to the Fc constant region. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, comprises a variant Fc constant region, wherein a water soluble polymer is linked to the Fc constant region.
- the antibody, or an antigenbinding fragment thereof comprises a variant Fc constant region, wherein a polyethylene glycol polymer is linked to the Fc constant region. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, comprises a variant Fc constant region, wherein a polyoxazoline polymer is linked to the Fc constant region.
- the antibody, or an antigen-binding fragment thereof comprises a variant Fc constant region, wherein the variant Fc constant region provides a longer half-life in vivo in a subject relative to the parental antibody, decreased immunogenicity in vivo in a subject relative to the parental antibody, or a combination of the foregoing.
- the antibody, or an antigen-binding fragment thereof is a human antibody. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, is a chimeric antibody. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, is a class- switched antibody.
- the antibody, or an antigen-binding fragment thereof is linked to a therapeutic agent. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, is linked to a detectable label. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, is linked to an enzyme. In certain embodiments of the first to tenth aspects, the antibody, or an antigen-binding fragment thereof, is linked to an enzyme inhibitor.
- the antibody, or an antigen-binding fragment thereof is an antigen-binding fragment.
- the antibody, or an antigen-binding fragment thereof is an antigen-binding fragment selected from the groups consisting of: a Fab fragment, a F(ab)2 fragment, a Fab' fragment, a Fd fragment, a Fv fragment, a disulfide-linked Fv (sdFv), a dAb fragment, an isolated CDR, a nanobody or single domain antibody, a portion of the VH region containing a single variable domain and two constant domains, a diabody, a triabody, a tetrabody, scFv, scFv-FC, scFv-CH, scFab, and scFv-zipper.
- the antibody, or an antigen-binding fragment thereof, the amino acid sequence of the antibody, or an antigen-binding fragment thereof has at least 85% homology to the reference sequence, at least 90% homology to the reference sequence, at least 95% homology to the reference sequence, at least 96% homology to the reference sequence, at least 97% homology to the reference sequence, at least 98% homology to the reference sequence, or at least 99% homology to the reference sequence.
- the antibody, or an antigen-binding fragment thereof, the amino acid sequence of the antibody, or an antigen-binding fragment thereof is 100% homologous to the reference sequence across the CDRs and has at least 85% homology to the reference sequence across the FRs, at least 85% homology to the reference sequence across the FRs, at least 90% homology to the reference sequence across the FRs, at least 95% homology to the reference sequence across the FRs, at least 96% homology to the reference sequence across the FRs, at least 97% homology to the reference sequence across the FRs, at least 98% homology to the reference sequence across the FRs, or at least 99% homology to the reference sequence across the FRs.
- the antibody, or an antigen-binding fragment thereof is used in combination with other anti-viral agents as described herein, such as inhibitors of viral RNA polymerase activity and/or other serine and non-serine protease inhibitors.
- a subject is infected with SARs-CoV- 2 and by one or more additional viruses.
- the antibody, or an antigen-binding fragment thereof is administered in an effective amount. Suitable effective amounts are described in more detail herein.
- the administering step may comprise administering a single dose of an antibody, or an antigen-binding fragment thereof, according to a course of treatment (where the dose may contain an effective amount).
- the administering step may comprise administering more than one dose of the antibody, or an antigen-binding fragment thereof, according to a course of treatment (where one or more doses may contain an effective amount).
- the antibody, or an antigen-binding fragment thereof, in each dose administered during a course of treatment is not required to be the same.
- the administering step may comprise administering at least one loading dose and at least one maintenance dose during a course of treatment.
- the administering step comprises administering a single dose or a plurality of doses comprising the antibody, or an antigen-binding fragment thereof, according to a course of treatment. In certain embodiments of the first to tenth aspects, the administering step comprises administering a dose or a plurality of doses comprising the antibody, or an antigen-binding fragment thereof, by intravenous administration according to a course of treatment. In certain embodiments of the first to tenth aspects, the administering step comprises administering a dose or a plurality of doses comprising the antibody, or an antigenbinding fragment thereof, by intranasal administration according to a course of treatment. In certain embodiments of the first to tenth aspects, the administering step comprises administering a dose or a plurality of doses comprising the antibody, or an antigen-binding fragment thereof, by pulmonary administration according to a course of treatment.
- the subject is suffering from or suspected of suffering from a SARS-CoV-2 infection.
- compositions and/or medicaments comprising the antibody, or an antigen-binding fragment thereof, may be administered according to the methods described herein.
- the subject is a mammal. In certain embodiments of the first to tenth aspects, the subject is a human.
- the administering step occurs before the subject has been infected with SARS-CoV-2 (/. «, the subject is at risk for infection), after the subject has been infected with SARS-CoV-2 (but before an infection can be detected), or after a subject has been infected with SARS-CoV-2 and the infection can be detected.
- the antibody, the subject is a healthcare worker, a first responder (for example, a policeman or a fireman), or a member of the military as such individuals may be required to undertake activities that place them at a higher risk of SARS-CoV-2 infection.
- a first responder for example, a policeman or a fireman
- a member of the military as such individuals may be required to undertake activities that place them at a higher risk of SARS-CoV-2 infection.
- the subject has travelled to a region where SARS-CoV-2 infections have been documented, the subject has had contact with a person who has travelled to a region where SARS-CoV-2 infections have been documented, the has had contact with a person who has a SARS-CoV-2 infection (including a SARS-CoV-2 infection that has not been detected) or is suspected of having a SARS-CoV-2 infection, the subject is a family member or acquaintance of a person who has a SARS-CoV-2 infection (including a CoV infection that has not been detected) or is at risk of having a SARS- CoV-2 infection, the subj ect is an infant or child (for example, a subject under the age of 18 years) who has a caregiver or parent who has a SARS-CoV-2 infection or is at risk of having a SARS- CoV-2 infection.
- the subject may be suffering from pulmonary disease, cardiovascular disease, diabetes mellitus, bacterial superinfection, sepsis syndrome, hypertension, chronic lung disease (inclusive of asthma, chronic obstructive pulmonary disease, and emphysema), chronic renal disease, chronic liver disease, immunodeficiency, an immunocompromised condition, neurologic disorder, neurodevelopmental, or intellectual disability.
- chronic lung disease inclusive of asthma, chronic obstructive pulmonary disease, and emphysema
- chronic renal disease chronic liver disease
- immunodeficiency an immunocompromised condition
- neurologic disorder neurodevelopmental, or intellectual disability.
- the antibody, or an antigen-binding fragment thereof is administered parenterally, such as by intravenous administration, intramuscular administration, or subcutaneous administration, orally, or via the respiratory tract (for example, by pulmonary or intranasal administration).
- the antibody, or an antigen-binding fragment thereof is administered intravenously.
- the antibody, or an antigen-binding fragment thereof is administered intramuscularly.
- the antibody, or an anti gen -binding fragment thereof is administered intranasally.
- compositions or methods described herein may further comprise one or more additional anti-viral agents in combination with an antibody of the disclosure.
- additional anti-viral agents include, but are not limited to, those agent that inhibit replication of SARS-CoV-2, such by inhibition of a RNA polymerase activity of SARS- CoV-2, and protease inhibitors, including but not limited to, serine protease inhibitors (for example, inhibitors of TMPRSS2) and cysteine protease inhibitors.
- Representative agents include, but are not limited to, galidesivir, remdisivir, hydrochloroquine, chloroquine, irbesartan, toremifene, camphor, equiline, mesalazine, mercaptopurine, nafamostat, paraoxetine, sirolimus, carvedilol, dactinomycin, melatonin, quinacrine, eplerenone, enoclin, oxymethalone, ENU2000, azithromycin, lopinovir/ritonavir, umifenovir, cytovene, ganciclovir, trisodium phosphonoformate, ribavirin, interferon, d4T, ddl, AZT, amantadine, rimantadine, acyclovir, foscarnet, laninamivir, oseltamivir, zanamivir, favipiravir,
- the polypeptides of the disclosure are administered to the subject (or are contacted with cells of the subject) in an effective amount.
- an effective amount decreases the viral titer of SARS-CoV-2 in the subject and/or limits or prevents an increase in the viral titer of SARS-CoV-2 viral particles in the subj ect.
- an effective amount decreases viral entry of SARS-CoV-2 subject.
- an effective amount reduces binding of SARS-CoV-2 to a target cell.
- an effective amount reduces cellular fusion between SARS-CoV-2 and a target cell.
- an effective amount reduces release of infective SARS-CoV-2 from an infected cell of the subject.
- an effective amount reduces infection of a target cell by SARS-CoV-2.
- the effective amount of an antibody of the disclosure ranges from about 0.01 mg/kg to about 100 mg/kg.
- the effective amount of an antibody of the disclosure ranges from: i) about 1 mg/kg to about 5 mg/kg; ii) about 1 mg/kg to about 4 mg/kg; iii) about 1 mg/kg to about 4 mg/kg; or iv) about 1 mg/kg to about 4 mg/kg.
- the effective amount described herein are administered every day, every other day, every three days, every 4 days, every 5 days, every six days or every seven days. In certain embodiments, the effective amount described herein are administered in weekly intervals (such as every week, every 2 weeks, every three weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, or longer). In certain embodiments, the effective amount described herein are administered in monthly intervals (such as every month, every 2 months, every three months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, every 12 months, or longer).
- an effective amounts is administered every day during a course of treatment.
- the effective amount per day may be administered in a single dose or in more than 1 dose per day (such as two to three doses per day).
- the effective amount per day is administered as a single dose per day.
- the effective amount per day is administered in two doses each day (/.c., b i d ), wherein the amount of the antibody in each dose need not be the same.
- the effective amount described above is administered every other day, every three days, every 4 days, every 5 days, every six days, or every seven days during a course of treatment.
- the effective amount in the dosing schedules may be administered in a single dose or in more than 1 dose (such as two to three doses).
- the effective amount in the dosing schedules is administered as a single dose on the day of administration.
- the effective amount in the dosing schedules is administered in two doses on the day of administration, wherein the amount of the antibody in each dose need not be the same.
- the effective amounts described above are administered in weekly intervals (such as every week, every 2 weeks, every three weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, or longer), during a course of treatment.
- the effective amount per weekly interval may be administered in a single dose or in more than 1 dose.
- the effective amount per week is administered as a single dose on the day of administration.
- the effective amount per week is administered in two doses on the day of administration, wherein the amount of the antibody in each dose need not be the same.
- the effective amounts described above are administered in monthly intervals (such as every month, every 2 months, every three months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, every 12 months, or longer), during a course of treatment.
- the effective amount per monthly interval may be administered in a single dose or in more than 1 dose.
- the effective amount per month is administered as a single dose on the day of administration.
- the effective amount per month is administered in two doses on the day of administration, wherein the amount of the antibody in each dose need not be the same.
- the term “dose” refers to an amount of an antibody of the disclosure administered at a given time point. For example, if a course of treatment for an antibody of the disclosure is b.i.d (2 times/admini strati ons per day) for 7 days, each administrations on each of days 1-7 would comprise administering a dose (for 2 doses each day).
- each dose administered may contain the same amount of an antibody of the disclosure or one or more of doses administered may contain a greater or lesser amount of an antibody of the disclosure as compared to another dose administered on that day.
- the first dose administered may contain a first amount (z.e., 10 mg/kg) and the second dose administered may contain a second amount (i.e., 5 mg/kg).
- the first dose administered on day 1 may contain a first amount (i.e., 10 mg/kg)
- the second dose administered on day 1 may contain a second amount i.e., 5 mg/kg
- the two doses administered on each of days 2-4 may contain the second amount
- the two doses administered on each of days 5-7 may contain a third amount (i.e., 2 mg/kg).
- the administration schedule for the effective amount is not required to be the same.
- a course of treatment may call for an effective amount to be delivered monthly (either as a single dose or multiple doses) for the first 6 months, and then every three months (either as a single dose or multiple doses) for the next 12 months.
- the effective amount delivered at each administration during a course of treatment is not required to be the same.
- a course of treatment may call for an effective amount to be delivered monthly (either as a single dose or multiple doses) for the first 6 months, and then every two months (either as a single dose or multiple doses) for the next 6 months, wherein the effective amount for the first monthly administration is 10 mg/kg and the effective amount for the remaining monthly administration and the bi-monthly administrations is 2.5 mg/kg.
- any given dose may be delivered in a single unit dose form or more than one unit dose form.
- a dose when given by IV administration may be provided as a single IV infusion (z.e., a single 20 mg/kg IV infusion) or as two or more IV infusions administered one after the other and be considered a single dose (z.e., two 10 mg/kg IV infusions).
- a dose may be further divided into a sub-dose.
- a sub-dose might be, for example, a number of discrete loosely spaced administrations, such as multiple inhalations from an inhaler, by application of a plurality of drops into the eye, or multiple tablets for oral administration.
- the methods may comprise the administration of a single dose of an effective amount of an antibody of the disclosure during the entire course of treatment. In certain embodiments, more than one dose of an antibody of the disclosure is administered during a course of treatment. Therefore, the methods may comprise the administration of multiple doses of an antibody of the disclosure during the course of treatment. In certain embodiments, the course of treatment may range from 2 days to 1 month, from 2 days to 3 weeks, from 2 days to 2 weeks, or from 2 days to 1 week.
- the course of treatment may range from 1 month to 6 months, from 1 month to 12 months, from 1 month to 24 months, or from 1 month to 36 months. In certain embodiments, the course of treatment may range from 2 days to 6 days, from 2 days to 5 days, from 2 days to 4 days, or from 2 days to 3 days. In certain embodiments, a dose is delivered at least 1 time per day (z.e., 1 to 3 times) during the course of treatment. In certain embodiments, the course of treatment is continuous. In certain embodiments, a dose is not administered every day during the course of treatment (for example, a dose is be administered at least 1 time per day every other day during the course of treatment). Furthermore, the amount of an antibody of the disclosure in each dose need not be the same as discussed above. In certain embodiments, of the foregoing, one or more doses, preferably all of the doses, contain an effective amount of an antibody of the disclosure.
- a course of treatment may comprise administering at least one dose as a loading dose and at least one dose as a maintenance dose, wherein the loading dose contains a greater amount of an antibody of the disclosure as compared to the maintenance dose (such as, but not limited to, 2 to 10 times higher).
- the loading dose is administered initially, followed by administration of one or more maintenance doses through the remaining course of treatment.
- a loading dose of 10 mg/kg may be administered as the first dose on day 1, followed by maintenance doses of 2 mg/kg for the remainder of the course of treatment.
- a loading dose of 20 mg/kg may be administered as the first dose on day 1, followed by maintenance doses of 5 mg/kg as the second dose on day 1 and each dose on days 2-4, followed by maintenance doses of 2 mg/kg for the remainder of the course of treatment.
- a loading dose may be given as a dose that is not the first dose administered during a course of treatment.
- a loading dose may be administered as the first dose on day 1 and as a dose on one or more additional days (for example, day 4).
- a loading dose of 10 mg/kg may be administered as the first dose on day 1, followed by a maintenance dose of 2 mg/kg as the second dose on day 1 and each dose on days 2-3, followed by a loading dose of 10 mg/kg as the first dose on day 4, followed by a maintenance dose of 2 mg/kg for the remainder of the course of treatment.
- the loading dose may be the same (z.e., 10 mg/kg) or different (z. e. , 20 mg/kg for the first loading dose and 10 mg/kg for each other loading dose).
- the loading dose comprises 2 to 15 times more of an antibody of the disclosure as compared to a maintenance dose administered during the same course of treatment. In certain embodiments, the loading dose comprises 2 to 10 times more of an antibody of the disclosure as compared to a maintenance dose administered during the same course of treatment. In certain embodiments, the loading dose comprises 2 to 5 times more of an antibody of the disclosure as compared to a maintenance dose administered during the same course of treatment.
- one or more of the loading and maintenance doses preferably all of the loading and maintenance doses, contain an effective amount of an antibody of the disclosure.
- administration of one or more loading and/or maintenance doses may comprise administering one or more sub-doses and/or administering one or more unit dose forms.
- the course of treatment is initiated (i.e., the first dose administered) after a subject has been infected with SARS-CoV-2. In certain embodiments, the course of treatment is initiated any time after a subject has been infected with SARS-CoV-2. In certain embodiments, the course of treatment is initiated any time after a subject has been infected with SARS-CoV-2 and before an active SARS-CoV-2 infection can be detected (i.e., by laboratory diagnosis or other methods). In certain embodiments, the course of treatment is initiated any time during which a subject has an active SARS-CoV-2 infection (i.e., by laboratory diagnosis or other methods). In certain embodiments, the course of treatment is initiated 1-5 days after a subject has been infected with SARS-CoV-2. In certain embodiments, the course of treatment is initiated 5- 10 days after a subject has been infected with SARS-CoV-2.
- the course of treatment is initiated before a subject is infected with SARS-CoV-2 (i.e., a prophylactic administration).
- SARS-CoV-2 i.e., a prophylactic administration
- the subject may undergo a course of treatment with an antibody of the disclosure prior to travel to the region or prior to potential exposure.
- a subject may be someone that is not initially exposed to SARS-CoV-2 infection from a non-human vector source.
- the spouse or partner of someone who has been exposed to SARS-CoV-2 or who is at risk for exposure to SARS-CoV-2 may undergo a course of treatment with an antibody of the disclosure as well.
- Such a prophylactic use of the antibodies of the disclosure are beneficial not only to protect the subject that is administered an antibody of the disclosure, but also in protecting those the subject comes into contact with (for example, family members and co-workers).
- the dose may comprise an antibody of the disclosure alone or an antibody of the disclosure in a pharmaceutical composition.
- each dose is delivered by parenteral administration.
- each dose is delivered by IV administration.
- each dose is delivered by IM administration.
- each dose is delivered by subcutaneous administration.
- each dose is delivered by via the pulmonary route.
- each dose is delivered by pulmonary administration.
- each dose is delivered by intranasal administration.
- each dose contains an amount of an antibody of the disclosure in a pharmaceutically acceptable form, such as a pharmaceutically acceptable salt.
- the antibodies of the disclosure may be formulated into pharmaceutical compositions for administration to subjects in a pharmaceutically acceptable form suitable for administration in vivo.
- the disclosure provides a pharmaceutical composition comprising antibodies of the disclosure in combination with a pharmaceutically acceptable carrier and/or excipient.
- the pharmaceutically acceptable carrier and/or excipient is chemically inert toward the active compounds and is non-toxic under the conditions of use.
- the pharmaceutically-acceptable carrier and/or excipient employed herein may be selected from various organic or inorganic materials that are used as materials for pharmaceutical compositions and which are incorporated as analgesic agents, buffers, wetting agents, emulsifying agents, pH adjusting agents, binders, disintegrants, diluents, emulsifiers, extenders, glidants, solubilizers, stabilizers, suspending agents, tonicity agents, vehicles, viscosity-increasing agents, antioxidants, colorants, flavor-improving agents, preservatives, and sweeteners.
- analgesic agents buffers, wetting agents, emulsifying agents, pH adjusting agents, binders, disintegrants, diluents, emulsifiers, extenders, glidants, solubilizers, stabilizers, suspending agents, tonicity agents, vehicles, viscosity-increasing agents, antioxidants, colorants, flavor-improving agents, pre
- the disclosure provides a pharmaceutical composition comprising an antibody of the disclosure, wherein the pharmaceutical composition comprises 1 to 6,000 mg of the antibody.
- the pharmaceutical composition may contain 1 to 2,000 mg, 1 to 600 mg, 1 to 500 mg, 1 to 400 mg, 1 to 300 mg, 1 to 200 mg, or 1 to 100 mg of the antibody.
- the antigen of the disclosure is present in the pharmaceutical composition at a concentration of at least 1 mg/mL, 5 mg/mL, 10 mg/mL, 50 mg/mL, 100 mg/mL, 150 mg/mL, 200 mg/mL, 300 mg/mL, 400 mg/mldress or 500 mg/ml (with the concentration in each of the foregoing being less than 750 mg/ml).
- the amount of an antibody of the disclosure in a pharmaceutical composition may very as is known in the art. Generally, the amount of an antibody of the disclosure will range from about 0.01% to about 99% by total weight of the pharmaceutical composition, preferably from about 0.1% to about 70%, from about 0.5% to 50%, or from about 1% to about 30%.
- Examples of pharmaceutically acceptable carriers may include, for example, water or saline solution, polymers such as polyethylene glycol, carbohydrates and derivatives thereof, oils, fatty acids, or alcohols.
- the pharmaceutically acceptable carrier is saline or water.
- the pharmaceutically acceptable carrier is saline.
- the pharmaceutically acceptable carrier is water or a saline solution.
- Surfactants such as, but not limited to, detergents, are also suitable for use in the formulations.
- Specific examples of surfactants include polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and of vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol or polyoxyethylenated esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as methacrylates and others, anionic surfactants, such as alkaline stearates, in particular sodium, potassium or ammonium stearate; calcium stearate or triethanolamine stearate; alkyl sulfates, in particular sodium lauryl sufate and sodium cetyl sulfate; sodium dodecylbenzenesulphonate or sodium dioctyl sulphosuccinate; or fatty acids, in particular those derived from coconut
- the pharmaceutical composition When administered to a subject, the pharmaceutical composition is preferably sterile.
- the pharmaceutical compositions of the disclosure are prepared by methods well-known in the pharmaceutical arts.
- the antibodies of the disclosure are brought into association with a carrier and/or excipient, as a suspension or solution.
- one or more accessory ingredients e.g, buffers, flavoring agents, surface active agents, and the like.
- the choice of carrier and/or excipient is determined by the solubility and chemical nature of the antibodies, chosen route of administration and standard pharmaceutical practice.
- the pharmaceutical composition comprises an antibody of the disclosure and water.
- the formulation comprises an antibody of the disclosure and saline.
- a pharmaceutical composition of the disclosure may be presented as capsules, tablets, powders, granules, or as a suspension or solution.
- Capsule formulations may be gelatin, soft-gel or solid. Tablets and capsule formulations may further contain one or more adjuvants, binders, diluents, disintegrants, excipients, fillers, or lubricants, each of which are known in the art.
- Such include carbohydrates such as lactose or sucrose, dibasic calcium phosphate anhydrous, corn starch, mannitol, xylitol, cellulose or derivatives thereof, microcrystalline cellulose, gelatin, stearates, silicon dioxide, talc, sodium starch glycolate, acacia, flavoring agents, preservatives, buffering agents, disintegrants, and colorants.
- Orally administered pharmaceutical compositions may contain one or more optional agents such as, but not limited to, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preservative agents, to provide a pharmaceutically palatable preparation.
- the antibodies of the disclosure may be combined with a sterile aqueous solution that is isotonic with the blood of the subject.
- a sterile aqueous solution that is isotonic with the blood of the subject.
- Such a formulation may be prepared by dissolving a solid active ingredient in water containing physiologically-compatible substances, such as sodium chloride, glycine and the like, and having a buffered pH compatible with physiological conditions, so as to produce an aqueous solution, then rendering said solution sterile.
- the formulation may be presented in unit dose form, such as sealed ampules or vials.
- the formulation may be delivered by any mode of injection, including, without limitation, epifascial, intracapsular, intracranial, intracutaneous, intrathecal, intramuscular, intraorbital, intraperitoneal, intraspinal, intrasternal, intravascular, intravenous, inhalation, intranasal, parenchymatous, subcutaneous, or sublingual or by way of catheter into the subject's body.
- a preferred mode of administration is intravenous, intramuscular, or intranasal.
- Parenteral administration includes aqueous and non-aqueous based solutions.
- aqueous and non-aqueous based solutions examples include, for example, water, saline, aqueous sugar or sugar alcohol solutions, alcoholic (such as ethyl alcohol, isopropanol, glycols), ethers, oils, glycerides, fatty acids, and fatty acid esters.
- water is used for parenteral administration.
- saline is used for parenteral administration.
- Oils for parenteral injection include animal, vegetable, synthetic or petroleum based oils.
- sugars for solution include sucrose, lactose, dextrose, mannose, and the like.
- oils include mineral oil, petrolatum, soybean, corn, cottonseed, peanut, and the like.
- fatty acids and esters include oleic acid, myristic acid, stearic acid, isostearic acid, and esters thereof.
- water is the excipient and/or carrier when the antibody of the disclosure is administered intravenously.
- the excipient and/or carrier is a saline solution when the antibody of the disclosure is administered intravenously.
- the excipient and/or carrier is a lactated Ringer’s solution when the antibody of the disclosure is administered intravenously.
- Aqueous dextrose and glycerol solutions may also be employed as an excipient and/or carrier when the antibody of the disclosure is administered intravenously.
- the antibodies of the disclosure can be formulated into aerosol formulations to be administered via the respiratory tract (for example, pulmonary or nasal administration). These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, and nitrogen. Such aerosol formulations may be administered by metered dose inhalers. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.
- the antibodies of the disclosure may be administered in an aqueous solution as a nasal or pulmonary spray and may be dispensed in spray form by a variety of methods known to those skilled in the art.
- the formulations may be presented in multi-dose containers, for example in the sealed dispensing system disclosed in U.S. Pat. No. 4,511,069.
- Additional aerosol delivery forms may include, e.g., compressed air-, jet-, ultrasonic-, and piezoelectric nebulizers, which deliver the active agent dissolved or suspended in a pharmaceutical solvent, e.g., water, ethanol, or a mixture thereof.
- Nasal and pulmonary solutions of the disclosure typically comprise the drug or drug to be delivered, optionally formulated with a surface-active agent, such as a nonionic surfactant (e.g., polysorbate-80), and one or more buffers.
- a surface-active agent such as a nonionic surfactant (e.g., polysorbate-80)
- the nasal spray solution further comprises a propellant.
- the pH of the nasal spray solution is optionally between about pH 3.0 and 6.0, preferably 4.5+-0.5.
- Suitable buffers for use within these compositions are as described above or as otherwise known in the art.
- Other components may be added to enhance or maintain chemical stability, including preservatives, surfactants, dispersants, or gases.
- Suitable preservatives include, but are not limited to, phenol, methyl paraben, paraben, m-cresol, thimerosal, chlorobutanol, benzylalkonimum chloride, and the like.
- Suitable surfactants include, but are not limited to, oleic acid, sorbitan trioleate, polysorbates, lecithin, phosphatidyl cholines, and various long chain diglycerides and phospholipids.
- Suitable dispersants include, but are not limited to, ethylenediaminetetraacetic acid, and the like.
- gases include, but are not limited to, nitrogen, helium, chlorofluorocarbons (CFCs), hydrofluorocarbons (HFCs), carbon dioxide, air, and the like.
- nasal and pulmonary formulations are administered as dry powder formulations comprising the active agent in a dry, usually lyophilized, form of an appropriate particle size, or within an appropriate particle size range, for intranasal delivery.
- Minimum particle size appropriate for deposition within the nasal or pulmonary passages is often about 0.5 pm. mass median equivalent aerodynamic diameter (MMEAD), commonly about 1 pm MMEAD, and more typically about 2 pm MMEAD.
- Maximum particle size appropriate for deposition within the nasal passages is often about 10 pm MMEAD, commonly about 8 pm MMEAD, and more typically about 4 pm MMEAD.
- Intranasally and pulmonary respirable powders within these size ranges can be produced by a variety of conventional techniques, such as jet milling, spray drying, solvent precipitation, supercritical fluid condensation, and the like.
- These dry powders of appropriate MMEAD can be administered to a patient via a conventional dry powder inhaler (DPI), which relies on the patient's breath, upon pulmonary or nasal inhalation, to disperse the power into an aerosolized amount.
- DPI dry powder inhaler
- the dry powder may be administered via air-assisted devices that use an external power source to disperse the powder into an aerosolized amount, e.g., a piston pump.
- the active agent can be combined with various pharmaceutically acceptable additives, as well as a base or carrier for dispersion of the active agent(s).
- Desired additives include, but are not limited to, pH control agents, such as arginine, sodium hydroxide, glycine, hydrochloric acid, citric acid, etc.
- local anesthetics e.g, benzyl alcohol
- isotonizing agents e.g., sodium chloride, mannitol, sorbitol
- adsorption inhibitors e.g., Tween 80
- solubility enhancing agents e.g., cyclodextrins and derivatives thereof
- stabilizers e.g., serum albumin
- reducing agents e.g., glutathione
- the tonicity of the formulation is typically adjusted to a value at which no substantial, irreversible tissue damage will be induced in the nasal mucosa at the site of administration.
- the tonicity of the solution is adjusted to a value of about 1/3 to 3, more typically 1/2 to 2, and most often 3/4 to 1.7.
- the antibodies of the disclosure may be dispersed in a base or vehicle, which may comprise a hydrophilic compound having a capacity to disperse the active agent and any desired additives.
- the base may be selected from a wide range of suitable carriers, including but not limited to, copolymers of polycarboxylic acids or salts thereof, carboxylic anhydrides (e.g., maleic anhydride) with other monomers (e.g., methyl (meth)acrylate, acrylic acid, etc.), hydrophilic vinyl polymers such as polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose, etc., and natural polymers such as chitosan, collagen, sodium alginate, gelatin, hyaluronic acid, and nontoxic metal salts thereof.
- suitable carriers including but not limited to, copolymers of polycarboxylic acids or salts thereof, carboxylic anhydrides (e.g., male
- a biodegradable polymer is selected as a base or carrier, for example, polylactic acid, poly(lactic acid-glycolic acid) copolymer, polyhydroxybutyric acid, poly(hydroxybutyric acid-glycolic acid) copolymer and mixtures thereof.
- synthetic fatty acid esters such as polyglycerin fatty acid esters, sucrose fatty acid esters, etc. can be employed as carriers.
- Hydrophilic polymers and other carriers can be used alone or in combination, and enhanced structural integrity can be imparted to the carrier by partial crystallization, ionic bonding, crosslinking and the like.
- the carrier can be provided in a variety of forms, including, fluid or viscous solutions, gels, pastes, powders, microspheres and films for direct application to the nasal mucosa.
- the use of a selected carrier in this context may result in promotion of absorption of the active agent.
- the antibodies of the disclosure are in unit dose form such as a tablet, capsule, infusion bag for intravenous administration, or single-dose vial.
- Suitable unit dose forms may contain and effective amount (including specific examples of an effective amount described herein), The effective amount may be determined and/or modified during clinical trials designed appropriately for each of the conditions for which administration of an antibody of the disclosure is indicated and will, of course, vary depending on the desired clinical endpoint.
- the disclosure also provides articles of manufacture for treating and preventing disorders, such as a SARS-CoV-2 infection, in a subject.
- the articles of manufacture comprise an antibody of the disclosure or a pharmaceutical composition comprising an antibody of the disclosure, optionally further containing at least one additional antiviral compound, as described herein.
- the articles of manufacture may be packaged with indications for various disorders that the pharmaceutical compositions are capable of treating and/or preventing.
- the articles of manufacture may comprise a unit dose of an antibody of the disclosure that is capable of treating or preventing a certain disorder, and an indication that the unit dose is capable of treating or preventing a certain disorder, for example a SARS-CoV-2 infection.
- the antibodies of the disclosure may be used for detection and diagnosis of SARS-CoV-2. Detection may occur by any known means in the art, for example, by immunoassay, including ELISA.
- immunoassays include, but are not limited to, enzyme immune assays (EIA), ELISPOT (enzyme-linked immunospot), radioimmunoassays (RIAs), immunofluorescence, and other assays known in the art, including but not limited to Western Blot analysis and/or immunoprecipitation methods.
- a buffered solution of an antigen or a sample containing an antigen is added to a well of a microtiter plate.
- a solution of non-reacting protein is then added to the well to prevent non-specific binding.
- An antibody of the disclosure, or antigen-binding fragment thereof is added.
- Such antibody or antigen binding fragment may be typically conjugated to a reporter molecule, such as, but not limited to, luciferase, horse-radish peroxidase, alkaline phosphatase, or P-D-galactosidase.
- the antibody of the disclosure is not conjugated to a reporter molecule
- secondary antibody that recognized the antibody of the disclosure may be added that is conjugated to a reporter molecule.
- a substrate for the reporter molecule is then added, which leads to a detectable signal.
- ELISAs may be run in a qualitative or quantitative format. Qualitative results provide a simple positive or negative result (yes or no) for a sample. A competitive ELISA may also be used.
- an unlabeled antibody of the disclosure, or antigen-binding fragment thereof, (the primary antibody, which may be conjugated to a reporter molecule or unlabeled) is incubated in the presence of a sample containing the antigen, which mixture is then added to a microtiter plate which is coated with the same antigen (the reference antigen) antigen-coated well. The plate is washed so as to remove unbound antibodies. If the primary antibody is not conjugated to a reporter molecule, a secondary antibody conjugated to a reporter molecule that is specific to the primary antibody is added to generate the detectable signal. Depending on the amount of antigen in the sample, more or less primary antibody will be available to bind the reference antigen.
- a known quantity of an antigen is linked to a radioactive tracer, such as, but not limited to, 1-125, which is then mixed with a known amount of antibody of the disclosure to bind to an antigen (such as SARS-CoV-2 spike protein).
- an antigen such as SARS-CoV-2 spike protein.
- a sample containing unknown quantity of the antigen is added and as the concentration of unlabeled antigen is increased, the binding between the antibodies and the labeled standard is decreased, which is directly measurable by measuring radioactivity.
- the present disclosure provides a method for the determination (such as an immunoassay determination) of SARS-CoV-2 in a patient, the method comprising: a) incubating a bodily sample from the patient with at least one isolated antibody, or an antigen-binding fragment thereof, of any one of claims 2 to 37 and a detectable label, wherein the detectable label is present on the antibody, or antigen binding fragment thereof, or the detectable label is present on a binding partner for either the SARS-CoV-2 or the antibody, or the antigen binding fragment thereof, to form an immunological complex containing the determinable group; and b) determining the presence of the detectable label in the sample, wherein the presence of the detectable label indicates SARS-CoV-2 is present in the sample.
- such method may further comprise isolating the immunological complex from the sample and determining the presence of the detectable label in either in the isolated immunological complex or in the sample remaining.
- the bodily sample is a serum sample, a blood sample, a plasma sample, a throat swab sample, a nasopharyngeal swab sample, a sputum sample, a fecal sample, a urine sample, a saliva sample, or a bronchoalveolar lavage fluid sample.
- any assay described herein may be used for diagnostic purposes. Therefore, the disclosure provides for methods of diagnosing SARS-CoV-2 infection in a subject using the antibodies of the disclosure. Such a diagnostic use may be directed to determining if a SARS-CoV-2 infection is present, monitoring recovery from a SARS-CoV-2 infection, evaluating the efficacy of a therapeutic treatment for treating a SARS-CoV-2 infection, and for other purposes known in the art.
- Kits The disclosure also provides a kit for use in the methods described herein, the kit comprising an antibody of the disclosure, or a pharmaceutically acceptable form thereof, and at least one of the following: (i) at least one other therapeutic agent; (ii) a buffer; (iii) instructions for administering the antibody of the disclosure, or pharmaceutically acceptable form thereof to a subject to treat a SARS-CoV-2 infection in the subject or detect SARS-CoV-2 in a sample (such as a sample from a subject).
- the subject is a human.
- the antibody is an antibody from Table 1 or Tables 2A-H, an antibody of the first to fourth embodiments, or any of the specific aspects of the first to fourth embodiments described above.
- Example 1 Identification. Purification. Sequencing, and Recombinant Production of SARS-CoV- 2 Specific Antibodies
- Peripheral blood samples were obtained from a single individual at the time of or following verified SARS-CoV-2 infection.
- Peripheral blood mononuclear cells PBMC were isolated by density gradient purification.
- PBMC peripheral blood mononuclear cells
- RBD SAR-CoV-2 Spike Receptor Binding Domain
- Single CD3- CD14- CD19+ RBD+ cells were sorted using a FACSMelody cell sorter (BD Biosciences) directly into 96-well PCR plates (Bio-Rad, Hercules, Calif.) containing 4 pL/well 0.5> ⁇ PBS with 10 mM DTT (Invitrogen), and 8 U RiboLock (ThermoFisher) RNAse inhibitor. Plates were sealed with MICROSEAL F FILM (Bio-Rad) and immediately frozen at -80° C until used for RT-PCR. cDNA was synthesized and semi-nested RT-PCR for IgH, IgX, and IgK V gene transcripts was performed as described in Kobie et al.
- IgGl expression vector cloning and transfection of human HEK293T cells were performed as previously described in Kobie et al. Monoclon Antib Immunodiagn Immunother. 2015 Apr. 1; 34(2): 65-72 and Tiller et al., J Immunol Methods. 2008 Jan. 1; 329(1-2): 112-124.
- PCR products were sequenced at Genewiz Sequences and analyzed by IgBlast and IMGT/V-QUEST to identify germline V(D)J gene segments with highest identity and to determine sequence properties (shown in Table 3).
- IgG was purified from culture supernatant using MAGNA PROTEIN G beads (Promega, Madison, Wis.).
- Table 3 provides a description of the SARS-CoV-2 hmAbs of the disclosure indicating the germline V(D)J for the heavy chain and light chain variable regions for each antibody as well as the original isotype of the antibody.
- Example 2 The Antibodies of the Disclosure Bind to SARS-CoV-2 Proteins To determine if the antibodies of the disclosure bound to SARS-CoV-2 spike protein, binding experiments were performed. ELISA plates were coated with the following recombinant SARS-CoV-2 polypeptides: i) SARS-CoV-2 receptor binding domain (RBD) polypeptide (SEQ ID NO: 162); ii) SARS-CoV-2 SI domain polypeptide (containing the RBD) (SEQ ID NO: 163); iii) SARS-CoV-2 SI and S2 domain polypeptide (SEQ ID NO: 164); and iv) SARS-CoV-2 nucleoprotein (N; negative control) (SEQ ID NO: 165).
- RBD SARS-CoV-2 receptor binding domain
- SEQ ID NO: 163 SARS-CoV-2 SI domain polypeptide (containing the RBD)
- SEQ ID NO: 163 SEQ ID NO: 163
- the CR3022 antibody (recombinant human anti-SARS-CoV monoclonal antibody that specifically binds to spike protein) served as a positive control while wells incubated with PBS only (no recombinant SARS-CoV-2 polypeptide) also served as a negative control.
- Recombinant SARS-CoV-2 polypeptides were coated at a concentration of 1 pg/ml and plates were blocked with 3% bovine serum albumin (BSA) in PBS.
- BSA bovine serum albumin
- the antibodies of the disclosure were diluted in PBS and tested at 1 and 10 pg/ml. Antibody binding was detected using horseradish peroxidase-conjugated anti-human IgG. The results are shown in FIG. 1, with the values expressed as area under the curve of the OD reading for both the 1 and 10 pg/ml antibody concentrations.
- the antibodies of the disclosure bound recombinant SARS- CoV-2 Spike protein polypeptides specifically, with no significant binding to the negative control SARS-CoV-2 N polypeptide.
- FIG. 1 also shows the antibodies of the disclosure showed more favorable binding to the recombinant SARS-CoV-2 RBD polypeptide as compared to the SARS- CoV-2 SI polypeptide and S1+S2 polypeptide.
- Antibodies 1213H7, 1206D1, 1212D4, 1206D12, 1207F10, and 1206G12 demonstrated 2-fold or greater binding to recombinant SARS-CoV-2 RBD polypeptide as compared to recombinant SARS-CoV-2 SI polypeptide, suggesting that at least a portion of the epitope may be masked in the full length SARS-CoV-2 Spike protein.
- antibodies 1212C2, 1212F2, 1212D5, 1206A5, 1212D6, and 1206D12 showed the least different in binding to recombinant SARS-CoV-2 RBD polypeptide as compared to recombinant SARS- CoV-2 SI polypeptide and S1+S2 polypeptide.
- Example 3 The Antibodies of the Disclosure Bind to SARS-CoV-2 Infected Cells
- Vero E6 cells were infected with SARS-CoV-2 virus (USA- WA1/2020 (Gen Bank: Accession No. MN985325.1) obtained from BEI Resources (NR-52281)) or mock infected and incubated for different times post-infection. Cells were then fixed with 4% neutral formaldehyde for 30 minutes followed by permeabilization using 0.5% triton X-100 for 15 minutes. Cells were then blocked with 2.5% Bovine Serum Albumin (BSA) at 37° C for 1 h.
- BSA Bovine Serum Albumin
- Example 4 The Antibodies of the Disclosure Neutralized SARS-CoV-2 Virus by SARS-CoV-2 Antibodies
- the ability of the antibodies of the disclosure to neutralize SARS-CoV-2 virus was analyzed using a plaque reduction microneutralization (PRMNT) assay. Since serial dilutions of the Ab containing samples are used, the PRMNT assay measures the neutralizing activity of Abs in a concentration dependent manner. The ability of a neutralizing antibody to inhibit virus infection is manifested in the reduced capacity of the virus to produce visible plaques when compared to virus-only infected control cells.
- the PRMNT assay is similar to a plaque reduction neutralization assay with the only difference that the PRMNT utilizes 96-well plates.
- the ability of the antibodies to neutralize SARS-CoV-2 virus was determined using two different approaches, a pre-treatment approach and a post-treatment approach.
- a pre-treatment approach antibodies of the disclosure are pre-incubated with SARS-CoV-2 at 37°C for Ih. This enables the antibodies to bind to the Spike protein blocking virus attachment, and subsequently interfering with the process of virus entry.
- virus adsorption is allowed to progress for Ih at 37°C. This gives the virus an opportunity to initiate viral entry by binding to the cell surface receptor (ACE2).
- ACE2 cell surface receptor
- Antibodies incubated with the infected cells may interfere with active viral replication partly by blocking later steps of the virus entry into the cell and/or by inhibiting the cell-to-cell spread of virus progeny.
- NT50 neutralization titer 50
- the post-treatment PRMNT assay offers a therapeutic evaluation of the neutralizing activity of Abs against SARS-CoV-2.
- the pretreatment PRMNT assay focuses on identifying antibodies targeting the SARS-CoV-2 Spike protein RBD
- the post-treatment PRMNT assay allows the identification of antibodies targeting other regions on the viral Spike protein involved in the proteolytic cleavage step (for example, the SI region), the fusion event (for example, the S2 region), or antibodies affecting other steps in the replication cycle of the virus (for example, virus assembly and/or budding).
- a potent SARS-CoV-2 neutralizing antibody will show a low NT50 titer whereas a weak neutralizing antibody will give a high NT50 value.
- 100 PFU/well of SARS-CoV-2 (USA-WA1/2020 from BEI Resources (NR-52281)) was mixed with decreasing concentrations of the antibodies of the disclosure (2-folds dilutions, starting concentration 25,000 ng/well for antibodies of the disclosure in 100 pl of infection media (DMEM with 1% penicillin-streptomycin-L-glutamate) and incubated at 37° C, 5% CO2 for Ih in infection media.
- Vero HL cells 96-well plate format, 4 x 10 4 cells/well, quadruplicate
- virus-antibody mixture were infected with virus-antibody mixture and incubated (virus adsorption) for Ih. After Ih incubation, the media was replaced with post-infection media (DMEM containing 2% FBS and 1% Avicel).
- Vero HL cells (96-well plate format, 4 x 10 4 cells/well, quadruplicate) in infection media were infected with 100 PFU/well of SARS-CoV-2 (USA- WA1/2020 from BEI Resources (NR-52281))). After 1 h of viral adsorption, the infection media was changed with the 100 pl of post-infection media containing decreasing concentrations of the antibodies of the disclosure (2-folds dilutions, starting 50,000 or 25,000 ng/ml for antibodies of the disclosure.
- infected cells (both pre-treatment and post-treatment) were fixed with 10% neutral formalin for 24 h and were immunostained using anti-NP (nucleoprotein) monoclonal 1C7C7 antibody.
- Virus neutralization was evaluated and quantified using ELISPOT, and the percentage of infectivity calculated using sigmoidal dose response curves. Mock-infected cells and viruses in the absence of the antibodies of the disclosure were used as internal controls.
- the results are shown in Table 4 below.
- the results show the antibodies of the disclosure are neutralizing SARS-CoV-2 antibodies.
- Nine of the antibodies tested displayed similar activity in the pre-treatment and post-treatment conditions (with NT50 values for the pre-treatment and post-treatment conditions being within 2-fold of one another).
- Eight of the antibodies tested displayed different activity in the pre-treatment and post-treatment conditions (with NT50 values for the pre-treatment and post-treatment conditions being greater 2-fold of one another).
- antibody 1212C2 exhibited potent neutralizing activity in both the pre-treatment and post-treatment conditions, with NT50 values ⁇ 50 ng/ml in each assay.
- Antibody 1212C2 exhibited strong binding to recombinant SARS-CoV-2 RBD polypeptide (FIG. 1).
- antibodies 1212F5 and 1213H7 exhibited potent neutralizing activity in both the pre-treatment and post-treatment conditions, with NT 50 values ⁇ 100 ng/ml in each assay.
- RBD was injected over the NmAbs at four concentrations (80nM, 20nM, 5nM, and 1.25nM) for 90 s, followed by 300 s dissociation phase. After each injection, the surface was regenerated with a 30 s pulse of 3M MgC12, followed by capture of fresh hmAb.
- the buffer flowrate for affinity analysis was 50 pL/min.
- Sensorgrams were globally fit to a 1 :1 model, without a bulk index correction, using Biacore T-200 evaluation software version 1.0. Standard errors for the rate constants were obtained from the fitted sensorgram data.
- Replicate KD errors were estimated by repeating the experiments for four of NmAb-RBD interactions (1212C2, 1206D1, 1215D1 and CB6/JS016). Standard deviations from these experiments were used to define an average KD error of 11%.
- Example 6 Broad and distinct neutralization of SARS-CoV-2 variants by SARS-CoV-2 antibodies SARS-CoV-2 has undergone substantial mutation, including within the Spike protein with such mutations impacting the ability of antibodies to recognize these emerging variants.
- Variants of Concern are particularly threatening to human health and have driven multiple waves of the SARS-CoV-2 pandemic.
- the defining mutations in spike for the VoC are as follows as reported by the US Center for Diseases Control and Prevention and Nexstrain. Beta: D80A, D215G, del241-243, K417N, E484K, N501Y, D614G, A701V.
- infected cells were fixed with 10% neutral formalin for 24 h and were immune- stained using anti-NP monoclonal 1C7C7 antibody.
- Virus neutralization was evaluated and quantified using ELISPOT, and the percentage of infectivity calculated using sigmoidal dose response curves.
- the formula to calculate percent viral infection for each concentration is given as [(Average # of plaques from each treated wells - average # of plaques from “no virus” wells)/(average # of plaques from “virus only” wells - average # of plaques from “no virus” wells)] x 100.
- a non-linear regression curve fit analysis over the dilution curve can be performed using GraphPad Prism to calculate NT50. Mock-infected cells and viruses in the absence of hmAb were used as internal controls.
- the SARS-CoV-2 antibodies demonstrate unique neutralization profiles against the SARS- CoV-2 variants.
- 1212C2 demonstrates potent neutralization with NT50 ⁇ 50 ng/ml for WAI, Delta, Epsilon, and rK417. Neutralization by 1212C2 is somewhat diminished for rN501 and is not evident for Beta, Gamma, rE484K, or the rK417N E484K N501Y triple mutation variant. This pattern is distinct from CB6/JS016, RGN10933, and RGN10987.
- 1213H7 is able to neutralize all the viruses tested which is in contrast to CB6/JS016 and RGN10933. 1213H7 has superior neutralizing activity against WAI and the rK417N E484K N501Y triple mutation variant compared to RGN1087.
- Example 7 Improved neutralization of SARS-CoV-2 by modifying 1212C2 heavy chain variable residues
- 1212C2-V1 (Fig. 4C) was created by introducing the I28T, I34M, H93Y, T96A, S114Y changes in to 1212C2 and resulted in 33% increase in neutralization potency.
- 1212C2-V2 (Fig. 4D) was created by introducing the Q1E, Q6E, I28T, D31A, I34L, H93Y, T96A, SI 14Y and resulted in at least a 44% increase in neutralization potency.
- Example 8 SARS-CoV-2 antibodies have prophylactic and therapeutic activity in hamsters
- SARS-CoV-2 antibodies 1212C2 and 1206D1 The in vivo activity of SARS-CoV-2 antibodies 1212C2 and 1206D1 was evaluated in the golden Syrian hamster model of SARS-CoV-2 infection.
- 10 mg/kg hmAb was administered by intraperitoneal (i.p.) injection 6 h before intranasal (i.n.) challenge with SARS-CoV-2.
- dpi In contrast, at 2 dpi, hamsters that received 1212C2 already started to exhibit meaningful viral load reduction in their nasal turbinate and lungs (Fig. 5A).
- virus was detected in the nasal turbinates and lungs of all of the hamsters in the PBS and isotype control groups, although an overall decrease compared to 2 dpi, consistent with the viral dynamics of SARS-CoV-2 infection in hamsters.
- prophylactically treated 1212C2 hamsters exhibited the eradication of viral loads in the nasal turbinates and lungs in 3 of 4 animals.
- 1206D1 hmAb exhibited modest activity, noted by 50% of hamsters having no detectable virus in the nasal turbinates and all 1206D1 hamsters having detectable virus in the lungs, although trending to lower titers compared to PBS and isotype control groups.
- 1212C2 demonstrated substantial prophylactic activity as seen in sterilizing protection in 63% of the hamsters.
- Therapeutic activity was tested by treatment with 25 mg/kg of 1212C2 6 h following i.n. infection of hamsters with SARS-CoV-2 and evaluating viral burden at 4 dpi only due to the limited availability of hmAb.
- SARS-CoV-2 was detected in the nasal turbinates in 3 of 4 animals in the PBS and isotype control groups. No virus was detected in the nasal turbinates of the 1212C2 treated hamsters.
- SARS-CoV-2 was detected in the lungs of all PBS and isotype control treated hamsters, but only in 1 of 4 of the 1212C2 treated hamsters (Fig. 5B).
- 1212C2 demonstrated substantial therapeutic activity, reducing virus to undetectable levels in 75% of the treated hamsters.
- SARS-CoV-2 infection in hamsters results in gross lung lesions, including consolidation, congestion, and atelectasis.
- Therapeutically, significantly less lung pathology was also observed in the 1212C2 treated hamster group compared to the PBS-treated group (p 0.0136), and ⁇ 58% reduction in lung pathology in the 1212C2 group compared to the control hamsters (Fig. 5D).
- these differences observed in lung lesions are consistent with the viral burden seen in the upper and lower respiratory tract (A+B).
- A+B upper and lower respiratory tract
- Therapeutic mAbs are typically delivered systemically through intravenous infusion or intramuscular injection. Such delivery typically results in ⁇ 0.1% of the injected dose in the lung epithelial lining fluid at Cmax, thus highly inefficient in achieving optimal concentrations in the respiratory tract for the protection or treatment of respiratory infections, such as SARS-CoV-2.
- Example 10 Inhaled delivery of 1212C2 provides more efficient therapeutic activity against SARS-CoV-2 infection in hamsters as compared to intraperitoneal delivery
- the crystallizable fragment (Fc) of 1212C2 was modified with the LALA mutation (z.e., a double mutation of Leu234Ala together with Leu235Ala) to reduce Fc receptor (FcR) binding and subsequent Fc-mediated effector functions, and further modified to increase half-life (referred to as 1212C2-HLE-LALA with the mutations M252Y/S254T/T256E (YTE)).
- LALA mutation z.e., a double mutation of Leu234Ala together with Leu235Ala
- FcR Fc receptor binding and subsequent Fc-mediated effector functions
- 1212C2-HLE-LALA with the mutations M252Y/S254T/T256E (YTE)
- Virus was not detectable in the lungs of any hamsters treated via IH with 1212C2-HLE-LALA at 16.3 mg/kg, and virus was lower in their nasal turbinates compared to controls. In contrast, virus was detectable at 2 dpi in the lungs of 50% of the hamsters treated i.p. with 1212C2-HLE-LALA at 25 mg/kg, and not significantly decreased in nasal turbinates compared to controls. At 2 dpi, virus was only detectable in the lungs of 25% and 50% of the hamsters treated via IH with lung-delivered doses of 3.2 mg/kg and 0.6 mg/kg 1212C2-HLE- LALA, respectively.
- inhaled 1212C2-HLE-LALA was superior in reducing viral titer in the lungs compared to i.p. administration.
- virus was detected in the nasal turbinates and lungs of all infected control hamsters (saline and isotype hmAb), with a trend toward modest non-specific reduction in viral titer in nasal turbinates only with isotype control hmAb (Fig. 6B).
- Viral titers were only sporadically detected in the nasal turbinates of the 1212C2 treated groups, with the exception of detectable virus in all of the 0.6 mg/kg inhaled 1212C2-HLE- LALA group.
- Example 11 SARS-CoV-2 antibodies prevent SARS-CoV-2 in mice
- mice 8C and 8D Nluc expression (Fig. 8E) and virus titers (Fig. 8F) in the nasal turbinate, lungs, and brains of 1212C2-treated mice.
- 1212C2 was able to protect mice from clinical symptoms of rSARS-CoV-2/Nluc-2A infection as determined by changes in body weight (Fig. 8G) and survival rate (Fig. 8H).
- mice were treated intraperitoneally (i.p.) with 25 mg/kg of 1212C2, 1213H7, or an IgG isotype control 24 h prior to challenge with 104 PFU of rSARS-CoV-2 Venus, rSARS-CoV-2 mCherry Beta, or both rSARS- CoV-2 Venus and rSARS-CoV-2 mCherry Beta together.
- Body weight (Fig. 9A) and survival (Fig. 9B) were evaluated for 12 days post-infection (pi).
- 1212C2 and 12137H7 similarly limited lung, nasal, and brain viral burden consistent with their activity against SARS-CoV-2 wild-type, or wild-type and Beta, respectively.
- lungs were collected to determine Venus and mCherry fluorescence expression using an Ami HT imaging system (Fig. 10A).
- BF bright field.
- Venus and mCherry radiance values were quantified based on the mean values for the regions of interest in mouse lungs (Fig. 10B).
- Mean values were normalized to the autofluorescence in mock-infected mice at each time point and were used to calculate fold induction.
- Gross pathological scores in the lungs of mock-infected and rSARS-CoV- 2-infected KI 8 hACE2 transgenic mice were calculated based on the % area of the lungs affected by infection.
- Viral titers in the lungs (top), nasal turbinate (middle) and brain (bottom) at days 2 and 4 pi were determined by plaque assay in Vero E6 cells. Bars indicates the mean and SD of lung virus titers. Dotted lines indicate the limit of detection. As shown in Fig. 1 ID, quantification of rSARS-CoV-2 Venus (WT) and rSARS-CoV-2 mCherry SA (Beta) in the lungs (top), nasal turbinate (middle) and brain (bottom) from mice co-infected with both rSARS-CoV-2 Venus (WT) and rSARS-CoV-2 mCherry SA (Beta) at days 2 and 4 pi.
- WT rSARS-CoV-2 Venus
- Beta rSARS-CoV-2 mCherry SA
- Example 14 Classification of SARS-CoV-2 antibodies by competition epitope mapping
- 1215D1, 1207B4, and 1207F10 mAbs were assigned to the C386-2/RBD complex, while 1212C2 was assigned to the C121/RBD complex.
- 1212C2 (modeled by C121-RBD) overlaps with Cl (modeled by P2C-1F11/RBD) and C2 NAbs, while 1215D1 (modeled by C386-2/RBD) can simultaneously bind with several Cl (1214D4, 1212C8, 1212D5 etc.) and CID (1213H7) mAbs.
- Constant exposure of SARS-CoV-2 to suboptimal levels of mAbs in infected individuals or in vitro can promote the selection of monoclonal antibody resistant mutant (MARM) SARS- CoV-2.
- MARMs were selected and identified using an in vitro model (Vero E6 cells) of SARS-CoV-2 infection (Fig. 14). Culture of SARS-CoV-2 in the presence of 1212C2, 1213H7, or 1215D1 resulted in the generation of MARM that had developed mutations within the Spike protein, resulting in loss of recognition by the mAb.
- the 1212C2 MARM has the E484K mutation in RBD.
- the 1212C2/RBD model identifies HCDR2 N53 and HCDR3 R103 as residues that interaction with RBD E484 and sterically prevents 1212C2 from binding to RBD E484K, These and additional residues form a pocket optimized for glutamic acid and smaller residues, but occlude lysine and Arginine sidechains at RBD E484.
- the 1213H7 MARM has RBD mutations G476D and F490S.
- Our current model of the 1213H7/RBD complex is of lower resolution than 1212C2 and 1215D1 interactions. Nonetheless, the 1213H7 has been assigned as having a CID epitope that binds on the opposite side of the RBD tip, relative to the 1215D1 epitope.
- This model is consistent with the competition epitope mapping.
- F490 sits in the center of the heavy chain binding site of the 1215D1/RBD model, which provides an initial explanation of 1215D 1 ’s sensitivity to the F490S MARM and validates the general location of the 1215D1/RBD model. Hydrophobic packing interactions, contributed from HCDR3 Fi l l is expected to be an important contributor to the 1215D1/RBD interactions.
- the mutations are described below in Table 8.
- the goals of this study were to compare and contrast the efficiency and kinetics of delivery of a human mAb to the lung tissues following IV, IN and IH routes of delivery. Measurements of delivery were determined by quantitating BAL, lung and serum titer that were evaluated for human IgG using a quantitative ELISA assay. The comparative analysis is shown in Fig. 15 and indicate IgG titer in serum, BAL and lung over a 24 hour of evaluation at 30mins, 6hrs, 12hrs and 24hrs following dosing by IV, IN or IH routes of delivery. It should be noted that the concentration of drug use in IV, IN and IH was different for each route and reflect differences in the efficiency of delivery.
- Example 17 Neutralization Assay for hmAbs alone or in combination
- the 1212C2, 1213H7, and 1215D1 mAbs were assessed both alone and in combination in a neutralizing antibody assay against WAI P7 (1.7x105 pfu/mL).
- 96-well plates were inoculated with lOOPFU/well (MOI 0.05), except for control wells containing no virus.
- Wells containing virus were treated with lOOng, 50.
- Ong of one or more antibodies for 24 hours in 1% Avicel media and NT50 was assessed pre- and posttreatment.
- NT50 for 1212C2 was 4.5ng and 3.2ng pre- and post-treatment, respectively.
- NT50 for 1213H7 was 6.6ng and 4.8ng pre- and post-treatment, respectively.
- NT 50 for 1215D1 was 22.6ng and 5.9ng pre- and post-treatment, respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021338380A AU2021338380A1 (en) | 2020-09-03 | 2021-09-03 | Human monoclonal antibodies to SARS-CoV-2 and use thereof |
EP21865212.1A EP4208479A1 (en) | 2020-09-03 | 2021-09-03 | Human monoclonal antibodies to sars-cov-2 and use thereof |
CA3190311A CA3190311A1 (en) | 2020-09-03 | 2021-09-03 | Human monoclonal antibodies to sars-cov-2 and use thereof |
JP2023514983A JP2023540759A (en) | 2020-09-03 | 2021-09-03 | Human monoclonal antibodies against SARS-CoV-2 and their use |
CN202180065874.3A CN116615450A (en) | 2020-09-03 | 2021-09-03 | Human monoclonal antibody against SARS-COV-2 and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063074207P | 2020-09-03 | 2020-09-03 | |
US63/074,207 | 2020-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022051650A1 true WO2022051650A1 (en) | 2022-03-10 |
Family
ID=80491552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/049112 WO2022051650A1 (en) | 2020-09-03 | 2021-09-03 | Human monoclonal antibodies to sars-cov-2 and use thereof |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4208479A1 (en) |
JP (1) | JP2023540759A (en) |
CN (1) | CN116615450A (en) |
AU (1) | AU2021338380A1 (en) |
CA (1) | CA3190311A1 (en) |
WO (1) | WO2022051650A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894674A (en) * | 2022-12-20 | 2023-04-04 | 厦门润康源生物科技有限公司 | Antibody for detecting coronavirus, preparation method and application thereof |
-
2021
- 2021-09-03 EP EP21865212.1A patent/EP4208479A1/en not_active Ceased
- 2021-09-03 CN CN202180065874.3A patent/CN116615450A/en active Pending
- 2021-09-03 CA CA3190311A patent/CA3190311A1/en active Pending
- 2021-09-03 WO PCT/US2021/049112 patent/WO2022051650A1/en active Application Filing
- 2021-09-03 JP JP2023514983A patent/JP2023540759A/en active Pending
- 2021-09-03 AU AU2021338380A patent/AU2021338380A1/en active Pending
Non-Patent Citations (4)
Title |
---|
BAUM ALINA, AJITHDOSS DHARANI, COPIN RICHARD, ZHOU ANBO, LANZA KATHRYN, NEGRON NICOLE, NI MIN, WEI YI, MOHAMMADI KUSHA, MUSSER BRE: "REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 370, no. 6520, 27 November 2020 (2020-11-27), US , pages 1110 - 1115, XP055848621, ISSN: 0036-8075, DOI: 10.1126/science.abe2402 * |
HAAGMANS BART L., NOACK DANNY, OKBA NISREEN M.A., LI WENTAO, WANG CHUNYAN, BESTEBROER THEO, DE VRIES RORY, HERFST SANDER, DE MEULD: "SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model", BIORXIV, 24 August 2020 (2020-08-24), XP055801768, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.08.24.264630v1.full.pdf> [retrieved on 20210505], DOI: 10.1101/2020.08.24.264630 * |
ZHENG ZHIQIANG, MONTEIL VANESSA MARTHE, MAURER-STROH SEBASTIAN, YEW CHOW WENN, LEONG CAROL, MOHD-ISMAIL NUR KHAIRIAH, CHEYYATRAIVE: "Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARSCoV-2", EUROSURVEILLANCE, CENTRE EUROPEEN POUR LA SURVEILLANCE EPIDEMIOLOGIQUE DU SIDA, FR, vol. 25, no. 28, 16 July 2020 (2020-07-16), FR , pages 1560 - 7917, XP055850940, ISSN: 1560-7917, DOI: 10.2807/1560-7917.ES.2020.25.28.2000291 * |
ZOST SETH J.; GILCHUK PAVLO; CHEN RITA E.; CASE JAMES BRETT; REIDY JOSEPH X.; TRIVETTE ANDREW; NARGI RACHEL S.; SUTTON RACHEL E.; : "Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 26, no. 9, 10 July 2020 (2020-07-10), New York, pages 1422 - 1427, XP037241576, ISSN: 1078-8956, DOI: 10.1038/s41591-020-0998-x * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894674A (en) * | 2022-12-20 | 2023-04-04 | 厦门润康源生物科技有限公司 | Antibody for detecting coronavirus, preparation method and application thereof |
CN115894674B (en) * | 2022-12-20 | 2023-07-25 | 厦门润康源生物科技有限公司 | Antibody for detecting coronavirus, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
JP2023540759A (en) | 2023-09-26 |
CA3190311A1 (en) | 2022-03-10 |
EP4208479A1 (en) | 2023-07-12 |
CN116615450A (en) | 2023-08-18 |
AU2021338380A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7116256B1 (en) | Anti-SARS-COV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
JP6719490B2 (en) | Anti-IL-36R antibody | |
US20210040223A1 (en) | Antibodies to Canine Interleukin-4 Receptor Alpha | |
JP2023518849A (en) | Human monoclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
US11858986B2 (en) | Interferon beta antibodies and uses thereof | |
JP2023528235A (en) | SARS-CoV-2 Antibodies and Methods of Selecting and Using The Same | |
WO2022098870A1 (en) | Neutralizing anti-sars-cov-2 antibodies | |
CA3199594A1 (en) | Antibodies against sars-cov-2 and uses thereof | |
TW202227489A (en) | Anti-par-2 antibodies and methods of use thereof | |
US20240166765A1 (en) | Inflammatory disease treatment using anti-tissue factor antibodies | |
JP2021525071A (en) | Hepatitis B antibody | |
EP4208479A1 (en) | Human monoclonal antibodies to sars-cov-2 and use thereof | |
CA3152511A1 (en) | Antibody compositions and methods for treating hepatitis b virus infection | |
US20240270828A1 (en) | Human neutralizing antibodies against sars-cov-2 spike s2 domain and uses thereof | |
CN116096402A (en) | Methods and compositions related to neutralizing antibodies against human coronaviruses | |
WO2024120516A1 (en) | Antibodies specifically binding to rsv | |
WO2023137399A2 (en) | Inflammatory disease treatment using anti-tissue factor antibodies | |
WO2022074621A1 (en) | Covid-19-binding immunoglobulins and methods for their use | |
WO2023235827A2 (en) | Coronavirus-inhibiting antibodies | |
WO2022162097A2 (en) | Antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21865212 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3190311 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023514983 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021338380 Country of ref document: AU Date of ref document: 20210903 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202317021217 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180065874.3 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021865212 Country of ref document: EP Effective date: 20230403 |